<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ENTECAVIR- entecavirÂ tablet, film coatedÂ </strong><br>Teva Pharmaceuticals USA Inc<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use entecavir tablets safely and effectively. See full prescribing information for entecavir tablets.<br>ENTECAVIR tablets for oral use<br>Initial U.S. Approval: 2005</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: SEVERE ACUTE EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B, PATIENTS CO-INFECTED WITH HIV AND HBV, and <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span>.</span></h1>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who have discontinued anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy, including entecavir. Hepatic function should be monitored closely for at least several months after discontinuation. Initiation of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted. (<a href="#i4i_section_id_62bab310-8f05-4b71-b2bc-94fb3aeeff8e">5.1</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Entecavir tablets are not recommended for patients co-infected with human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV) and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) who are not also receiving highly active antiretroviral therapy (HAART), because of the potential for the development of resistance to HIV nucleoside reverse transcriptase inhibitors. (<a href="#i4i_section_id_4c0e552a-fb83-400d-a62f-52d7ed779778">5.2</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogue inhibitors. (<a href="#i4i_section_id_5b91d053-b777-404f-bf94-167b841797ac">5.3</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"> </p>
<table width="100%">
<col width="50%">
<col width="12%">
<tbody class="Headless">
<tr class="First Toprule">
<td><p class="Highlighta">Indications and Usage (<span class="Underline"><a href="#i4i_indications_id_aaa9b6bc-6542-4890-bda9-06bbacc14df0">1</a></span>) </p></td>
<td><p class="Highlighta">3/2014 </p></td>
</tr>
<tr>
<td><p class="Highlighta">Dosage and Administration </p></td>
<td></td>
</tr>
<tr class="Botrule Last">
<td><p class="Highlighta">    <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (<span class="Underline"><a href="#i4i_section_id_43e32ad3-2d5b-44af-a8b7-637177e66ed8">2.4</a></span>) </p></td>
<td><p class="Highlighta">3/2014 </p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: SEVERE ACUTE EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B, PATIENTS CO-INFECTED WITH HIV AND HBV, and <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span>.</span></h1>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who have discontinued anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy, including entecavir. Hepatic function should be monitored closely for at least several months after discontinuation. Initiation of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted. (<a href="#i4i_section_id_62bab310-8f05-4b71-b2bc-94fb3aeeff8e">5.1</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Entecavir tablets are not recommended for patients co-infected with human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV) and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) who are not also receiving highly active antiretroviral therapy (HAART), because of the potential for the development of resistance to HIV nucleoside reverse transcriptase inhibitors. (<a href="#i4i_section_id_4c0e552a-fb83-400d-a62f-52d7ed779778">5.2</a>)</span></dd>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogue inhibitors. (<a href="#i4i_section_id_5b91d053-b777-404f-bf94-167b841797ac">5.3</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Entecavir tablets are a <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B virus nucleoside analog reverse transcriptase inhibitor indicated for the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. (<a href="#i4i_indications_id_aaa9b6bc-6542-4890-bda9-06bbacc14df0">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Nucleoside-inhibitor-treatment-naÃ¯ve with compensated liver disease (greater than or equal to 16 years old): 0.5 mg once daily. (<a href="#i4i_section_id_10352ad5-7cb3-47ef-9a6b-edcdb98edb82">2.2</a>)</dd>
<dt>â€¢</dt>
<dd>Lamivudine-refractory or known lamivudine or telbivudine resistance substitutions (greater than or equal to 16 years old): 1 mg once daily. (<a href="#i4i_section_id_10352ad5-7cb3-47ef-9a6b-edcdb98edb82">2.2</a>)</dd>
<dt>â€¢</dt>
<dd>Decompensated liver disease (adults): 1 mg once daily. (<a href="#i4i_section_id_10352ad5-7cb3-47ef-9a6b-edcdb98edb82">2.2</a>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: Dosage adjustment is recommended if creatinine clearance is less than 50 mL/min. (<a href="#i4i_section_id_a0f488ba-5707-49e4-a065-03339b0a30c6">2.4</a>)</dd>
<dt>â€¢</dt>
<dd>Entecavir tablets should be administered on an empty stomach. (<a href="#i4i_section_id_1bf6749d-07cb-49b1-ba6b-fd21bdca0785">2.1</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Tablets: 0.5 mg and 1 mg (<a href="#i4i_dosage_form_strength_id_c23021a2-2289-4581-b503-948cb0eec548">3</a>, <a href="#i4i_how_supplied_id_76860f33-dbdc-45c4-89e0-a54e69ba6da5">16</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>None. (<a href="#i4i_contraindications_id_4c669df0-9348-4f3d-885b-8f0d4421fdd1">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> after discontinuation: Monitor hepatic function closely for at least several months. (<a href="#i4i_section_id_62bab310-8f05-4b71-b2bc-94fb3aeeff8e">5.1</a>, <a href="#i4i_section_id_ba6f0ae2-457f-4abc-90f2-7114b3d0f569">6.1</a>)</dd>
<dt>â€¢</dt>
<dd>Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with HIV: Entecavir is not recommended unless the patient is also receiving HAART. (<a href="#i4i_section_id_4c0e552a-fb83-400d-a62f-52d7ed779778">5.2</a>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis: If suspected, treatment should be suspended. (<a href="#i4i_section_id_5b91d053-b777-404f-bf94-167b841797ac">5.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<dl>
<dt>â€¢</dt>
<dd>Most common adverse reactions (â‰¥ 3%, all severity grades) are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. (<a href="#i4i_section_id_ba6f0ae2-457f-4abc-90f2-7114b3d0f569">6.1</a>)</dd>
</dl>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact TEVA USA, PHARMACOVIGILANCE at 1-866-832-8537, or drug.safety@tevapharm.com; or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Nursing mothers: Discontinue nursing or entecavir taking into consideration the importance of entecavir to the mother. (<a href="#i4i_nursing_mothers_id_205fe8fe-e505-4191-bd2e-65ead379e69e">8.3</a>)</dd>
</dl></div>
<div><div><div></div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
<div><div></div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 7/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: SEVERE ACUTE EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B, PATIENTS CO-INFECTED WITH HIV AND HBV, AND <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Timing of Administration </a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Recommended Dosage in Adults</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Recommended Dosage in Pediatric Patients</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Duration of Therapy</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Severe Acute Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Patients Co-Infected With HIV and HBV</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> With Steatosis</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience in Adults</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Clinical Trial Experience in Pediatric Subjects</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 Racial/Ethnic Groups</a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.8" class="toc">8.8 Liver Transplant Recipients </a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.3" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Outcomes in Adults</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Outcomes in Pediatric Subjects</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-17.1" class="toc">Entecavir Tablets 0.5 mg, 30s Label Text</a></h2>
<h2><a href="#section-18.1" class="toc">Entecavir Tablets 1 mg, 30s Label Text</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="i4i_boxed_warning_id_731d8230-8d96-4a20-86b6-e9cfdc949105"></a><a name="section-1"></a><p></p>
<h1>WARNING: SEVERE ACUTE EXACERBATIONS OF <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">HEPATITIS</span> B, PATIENTS CO-INFECTED WITH HIV AND HBV, AND <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">LACTIC ACIDOSIS</span> AND <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">HEPATOMEGALY</span></h1>
<p class="First"><span class="Bold">Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who have discontinued anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy, including entecavir. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy. If appropriate, initiation of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_62bab310-8f05-4b71-b2bc-94fb3aeeff8e">5.1</a>)</span>].</span></p>
<p><span class="Bold">Limited clinical experience suggests there is a potential for the development of resistance to HIV (human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus) nucleoside reverse transcriptase inhibitors if entecavir tablets are used to treat <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus (HBV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> that is not being treated. Therapy with entecavir tablets is not recommended for HIV/HBV co-infected patients who are not also receiving highly active antiretroviral therapy (HAART) [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_4c0e552a-fb83-400d-a62f-52d7ed779778">5.2</a>)</span>].</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogue inhibitors alone or in combination with antiretrovirals [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_5b91d053-b777-404f-bf94-167b841797ac">5.3</a>)</span>].</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_aaa9b6bc-6542-4890-bda9-06bbacc14df0"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Entecavir tablets are indicated for the treatment of <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.</p>
<p>The following points should be considered when initiating therapy with entecavir tablets:</p>
<dl>
<dt>â€¢</dt>
<dd>In adult patients, this indication is based on clinical trial data in nucleoside-inhibitor-treatment-naÃ¯ve and lamivudine-resistant subjects with HBeAg-positive and HBeAg-negative HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and compensated liver disease and a more limited number of subjects with decompensated liver disease. [<span class="Italics">see Clinical Studies (<a href="#i4i_section_id_77a23d62-e753-42bc-abc8-01ca6ecfeb58">14.1</a>)</span>].</dd>
</dl>
<p>Pediatric use information is approved for Bristol-Myers Squibb Companyâ€™s Baraclude<span class="Sup">Â®</span> (entecavir) tablets. However, due to Bristol-Myers Squibb Companyâ€™s marketing exclusivity rights, this drug product is not labeled with that information.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_8e1d9cb2-f0f8-45b6-b841-7e5ce02be893"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1bf6749d-07cb-49b1-ba6b-fd21bdca0785"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Timing of Administration </h2>
<p class="First">Entecavir tablets should be administered on an empty stomach (at least 2 hours after a meal and 2 hours before the next meal).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_10352ad5-7cb3-47ef-9a6b-edcdb98edb82"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Recommended Dosage in Adults</h2>
<p class="First"><span class="Bold">Compensated Liver Disease</span></p>
<p>The recommended dose of entecavir tablets for <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in nucleoside-inhibitor-treatment-naÃ¯ve adults and adolescents 16 years of age and older is 0.5 mg once daily. </p>
<p>The recommended dose of entecavir tablets in adults and adolescents (at least 16 years of age) with a history of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B <span class="product-label-link" type="condition" conceptid="133327" conceptname="Viremia">viremia</span> while receiving lamivudine or known lamivudine or telbivudine resistance substitutions rtM204I/V with or without rtL180M, rtL80I/V, or rtV173L is 1 mg once daily. </p>
<p><span class="Bold">Decompensated Liver Disease</span></p>
<p>The recommended dose of entecavir tablets for <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in adults with decompensated liver disease is 1 mg once daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_df60bec1-4b02-4d54-8d6b-531e085a85c4"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Recommended Dosage in Pediatric Patients</h2>
<p class="First">Pediatric use information is approved for Bristol-Myers Squibb Companyâ€™s Baraclude<span class="Sup">Â®</span> (entecavir) tablets. However, due to Bristol-Myers Squibb Companyâ€™s marketing exclusivity rights, this drug product is not labeled with that information.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a0f488ba-5707-49e4-a065-03339b0a30c6"></a><a name="section-2.4"></a><p></p>
<h2>2.4 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">In adult subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the apparent oral clearance of entecavir decreased as creatinine clearance decreased [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_d9ded4af-763a-443b-95ae-0db06b88eb97">12.3</a>)</span>]. Dosage adjustment is recommended for patients with creatinine clearance less than 50 mL/min, including patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD), as shown in <span class="Bold">Table 2</span>. The once-daily dosing regimens are preferred.</p>
<a name="_RefIDC1F7AD0B237E4BDCA0838CED9D3DC8B8"></a><table width="100%">
<caption><span>Table 2: Recommended Dosage of Entecavir Tablets in Adult Patients With <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> </span></caption>
<col width="29%">
<col width="20%">
<col width="51%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>If administered on a hemodialysis day, administer entecavir tablets after the hemodialysis session.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Creatinine Clearance (mL/min)</span></p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Usual Dose (0.5 mg)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Lamivudine-Refractory or Decompensated Liver Disease <br>(1 mg)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">50 or greater</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.5 mg once daily</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 mg once daily</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">30 to less than 50</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.5 mg every 48 hours</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.5 mg once daily<br><span class="Bold">OR</span><br>1 mg every 48 hours</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First">10 to less than 30</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.5 mg every <br>72 hours</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 mg every 72 hours</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center"><p class="First">Less than 10<br>Hemodialysis<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> or CAPD</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.5 mg every 7 days</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 mg every 7 days</p></td>
</tr>
</tbody>
</table>
<p>Pediatric use information is approved for Bristol-Myers Squibb Companyâ€™s Baraclude<span class="Sup">Â®</span> (entecavir) tablets. However, due to Bristol-Myers Squibb Companyâ€™s marketing exclusivity rights, this drug product is not labeled with that information.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aea96f2b-75ae-43d1-9a48-2401497c73e7"></a><a name="section-2.5"></a><p></p>
<h2>2.5 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No dosage adjustment is necessary for patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_43e32ad3-2d5b-44af-a8b7-637177e66ed8"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Duration of Therapy</h2>
<p class="First">The optimal duration of treatment with entecavir tablets for patients with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the relationship between treatment and long-term outcomes such as cirrhosis and hepatocellular carcinoma are unknown.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_c23021a2-2289-4581-b503-948cb0eec548"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<dl>
<dt>â€¢</dt>
<dd>Entecavir Tablets, 0.5 mg are available as white to off-white, round, unscored, film-coated tablets, debossed with â€œTEVAâ€? on one side, and â€œ5786â€? on the other side. </dd>
<dt>â€¢</dt>
<dd>Entecavir Tablets, 1 mg are available as light-pink to pink, round, unscored, film-coated tablets, debossed with â€œTEVAâ€? on one side and â€œ5787â€? on the other side.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_4c669df0-9348-4f3d-885b-8f0d4421fdd1"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_5b5ba4a6-443c-41b1-8ed9-d8489da05bc5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_62bab310-8f05-4b71-b2bc-94fb3aeeff8e"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Severe Acute Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B</h2>
<p class="First">Severe acute exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B have been reported in patients who have discontinued anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy, including entecavir [<span class="Italics">see Adverse Reactions (<a href="#i4i_section_id_ba6f0ae2-457f-4abc-90f2-7114b3d0f569">6.1</a>)</span>]. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy. If appropriate, initiation of anti-<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy may be warranted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4c0e552a-fb83-400d-a62f-52d7ed779778"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Patients Co-Infected With HIV and HBV</h2>
<p class="First">Entecavir has not been evaluated in HIV/HBV co-infected patients who were not simultaneously receiving effective HIV treatment. Limited clinical experience suggests there is a potential for the development of resistance to HIV nucleoside reverse transcriptase inhibitors if entecavir is used to treat <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> in patients with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> that is not being treated [<span class="Italics">see Microbiology (<a href="#i4i_microbiology_id_cd45fa9a-4e9c-4d8e-9233-545dc108015d">12.4</a>)</span>]. Therefore, therapy with entecavir is not recommended for HIV/HBV co-infected patients who are not also receiving HAART. Before initiating entecavir therapy, HIV antibody testing should be offered to all patients. Entecavir has not been studied as a treatment for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> and is not recommended for this use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5b91d053-b777-404f-bf94-167b841797ac"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic Acidosis</span> and Severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> With Steatosis</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis, including fatal cases, have been reported with the use of nucleoside analogue inhibitors, including entecavir, alone or in combination with antiretrovirals. A majority of these cases have been in women. <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">Obesity</span> and prolonged nucleoside inhibitor exposure may be risk factors. Particular caution should be exercised when administering nucleoside analogue inhibitors to any patient with known risk factors for liver disease; however, cases have also been reported in patients with no known risk factors. </p>
<p><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> with entecavir use has been reported, often in association with hepatic decompensation, other serious medical conditions, or drug exposures. Patients with decompensated liver disease may be at higher risk for <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>. Treatment with entecavir should be suspended in any patient who develops clinical or laboratory findings suggestive of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or pronounced hepatotoxicity (which may include <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> and steatosis even in the absence of marked transaminase elevations).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_721be106-9456-4c5b-8f5c-0dbe43aecf54"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in other sections of the labeling:</p>
<dl>
<dt>â€¢</dt>
<dd>Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> after discontinuation of treatment [<span class="Italics">see <a href="#i4i_boxed_warning_id_731d8230-8d96-4a20-86b6-e9cfdc949105">Boxed Warning</a>, Warnings and Precautions (<a href="#i4i_section_id_62bab310-8f05-4b71-b2bc-94fb3aeeff8e">5.1</a>)</span>]. </dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> and severe <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span> with steatosis [<span class="Italics">see<a href="#i4i_boxed_warning_id_731d8230-8d96-4a20-86b6-e9cfdc949105"> Boxed Warning</a>, Warnings and Precautions (<a href="#i4i_section_id_5b91d053-b777-404f-bf94-167b841797ac">5.3</a>)</span>].</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ba6f0ae2-457f-4abc-90f2-7114b3d0f569"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience in Adults</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Bold">Compensated Liver Disease</span></p>
<p>Assessment of adverse reactions is based on four studies (AI463014, AI463022, AI463026, and AI463027) in which 1720 subjects with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and compensated liver disease received double-blind treatment with entecavir 0.5 mg/day (n = 679), entecavir 1 mg/day (n = 183), or lamivudine (n = 858) for up to 2 years. Median duration of therapy was 69 weeks for entecavir-treated subjects and 63 weeks for lamivudine-treated subjects in Studies AI463022 and AI463027 and 73 weeks for entecavir-treated subjects and 51 weeks for lamivudine-treated subjects in Studies AI463026 and AI463014. The safety profiles of entecavir and lamivudine were comparable in these studies. Â </p>
<p>The most common adverse reactions of any severity (â‰¥ 3%) with at least a possible relation to study drug for entecavir-treated subjects were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>. The most common adverse reactions among lamivudine-treated subjects were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. One percent of entecavir-treated subjects in these four studies compared with 4% of lamivudine-treated subjects discontinued for adverse events or abnormal laboratory test results.</p>
<p>Clinical adverse reactions of moderate-severe intensity and considered at least possibly related to treatment occurring during therapy in four clinical studies in which entecavir was compared with lamivudine are presented in <span class="Bold">Table 3</span>. </p>
<a name="_RefID418F775EF0454BBF9FC80CAC277C340D"></a><table width="100%">
<caption><span>Table 3: Clinical Adverse Reactions<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a> of Moderate-Severe Intensity (Grades 2 to 4) Reported in Four Entecavir Clinical Trials Through 2 Years </span></caption>
<col width="19%">
<col width="14%">
<col width="16%">
<col width="12%">
<col width="14%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Includes events of possible, probable, certain, or unknown relationship to treatment regimen.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">â€ </a></dt>
<dd>Studies AI463022 and AI463027.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">â€¡</a></dt>
<dd>Includes Study AI463026 and the entecavir 1 mg and lamivudine treatment arms of Study AI463014, a Phase 2 multinational, randomized, double-blind study of three doses of entecavir (0.1, 0.5, and 1 mg) once daily versus continued lamivudine 100 mg once daily for up to 52 weeks in subjects who experienced recurrent <span class="product-label-link" type="condition" conceptid="133327" conceptname="Viremia">viremia</span> on lamivudine therapy.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Nucleoside-Inhibitor-NaÃ¯ve</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Lamivudine-Refractory</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">â€¡</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="Bold">Body System/</span><br> Adverse Reaction</p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Entecavir </span><br><span class="Bold">0.5 mg</span><br><span class="Bold">n = 679</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Lamivudine</span><br><span class="Bold">100 mg</span><br><span class="Bold">n = 668</span></p></td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Entecavir </span></p>
<p><span class="Bold">1 mg</span><br><span class="Bold">n = 183</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Lamivudine</span><br><span class="Bold">100 mg</span><br><span class="Bold">n = 190</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Any Grade 2 to 4<br>adverse reaction<a href="#footnote-2" class="Sup">*</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">15%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">18%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">22%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">23%</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold">Gastrointestinal</span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold">General</span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3%</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold">Nervous System</span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5"><p class="First"><span class="Bold">Psychiatric</span></p></td></tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First"> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt; 1%</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics">Laboratory Abnormalities</span></span></p>
<p>Frequencies of selected treatment-emergent laboratory abnormalities reported during therapy in four clinical trials of entecavir compared with lamivudine are listed in <span class="Bold">Table 4</span>. </p>
<a name="_RefIDA0D4ED75F1A8414E818487ED5FCB23DB"></a><table width="100%">
<caption><span>Table 4: Selected Treatment-Emergent<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a> Laboratory Abnormalities Reported in Four Entecavir Clinical Trials Through 2 Years </span></caption>
<col width="42%">
<col width="14%">
<col width="16%">
<col width="12%">
<col width="14%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>On-treatment value worsened from baseline to Grade 3 or Grade 4 for all parameters except albumin (any on-treatment value &lt; 2.5 g/dL), confirmed creatinine increase â‰¥ 0.5 mg/dL, and ALT &gt; 10 x ULN and &gt; 2 x baseline. </dd>
<dt><a name="footnote-6" href="#footnote-reference-6">â€ </a></dt>
<dd>Studies AI463022 and AI463027.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">â€¡</a></dt>
<dd>Includes Study AI463026 and the entecavir 1 mg and lamivudine treatment arms of Study AI463014, a Phase 2 multinational, randomized, double-blind study of three doses of entecavir (0.1, 0.5, and 1 mg) once daily versus continued lamivudine 100 mg once daily for up to 52 weeks in subjects who experienced recurrent <span class="product-label-link" type="condition" conceptid="133327" conceptname="Viremia">viremia</span> on lamivudine therapy.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">Â§</a></dt>
<dd>Includes hematology, routine chemistries, renal and liver function tests, pancreatic enzymes, and urinalysis.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">Â¶</a></dt>
<dd>Grade 3 = 3+, large, â‰¥ 500 mg/dL; Grade 4 = 4+, marked, severe.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">#</a></dt>
<dd>Grade 3 = 3+, large; Grade 4 = â‰¥ 4+, marked, severe, many.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Nucleoside-Inhibitor-NaÃ¯ve</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Lamivudine-Refractory</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">â€¡</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Test</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Entecavir </span><br><span class="Bold">0.5 mg</span><br><span class="Bold">n = 679</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Lamivudine</span><br><span class="Bold">100 mg</span><br><span class="Bold">n = 668</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Entecavir </span><br><span class="Bold">1 mg</span><br><span class="Bold">n = 183</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Lamivudine</span><br><span class="Bold">100 mg</span><br><span class="Bold">n = 190</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Any Grade 3 to 4 laboratory abnormality<a name="footnote-reference-8" href="#footnote-8" class="Sup">Â§</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">35%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">36%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">37%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">45%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">ALT &gt; 10 x ULN and &gt; 2 x baseline</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">4%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">ALT &gt; 5 x ULN</p></td>
<td class="Botrule Lrule" align="center"><p class="First">11%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">16%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">12%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">24%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Albumin &lt; 2.5 g/dL</p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Total bilirubin &gt; 2.5 x ULN</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Lipase â‰¥ 2.1 x ULN</p></td>
<td class="Botrule Lrule" align="center"><p class="First">7%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">6%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">7%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">CreatinineÂ  &gt; 3 x ULN</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Confirmed creatinine increase â‰¥ 0.5 mg/dL</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, fasting &gt; 250 mg/dL</p></td>
<td class="Botrule Lrule" align="center"><p class="First">2%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">Glycosuria</span><a name="footnote-reference-9" href="#footnote-9" class="Sup">Â¶</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">4%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">3%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">4%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">#</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">9%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">10%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">9%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">6%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Platelets &lt; 50,000/mm<span class="Sup">3</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">&lt; 1%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">&lt; 1%</p></td>
</tr>
</tbody>
</table>
<p>ULN = upper limit of normal.</p>
<p>Among entecavir-treated subjects in these studies, on-treatment ALT elevations greater than 10 times the upper limit of normal (ULN) and greater than 2 times baseline generally resolved with continued treatment. A majority of these exacerbations were associated with a â‰¥ 2 log<span class="Sub">10</span>/mL reduction in viral load that preceded or coincided with the ALT elevation. Periodic monitoring of hepatic function is recommended during treatment.</p>
<p><span class="Bold"><span class="Italics">Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> after Discontinuation of Treatment </span></span></p>
<p>An exacerbation of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> or ALT flare was defined as ALT greater than 10 times ULN and greater than 2 times the subjectâ€™s reference level (minimum of the baseline or last measurement at end of dosing). For all subjects who discontinued treatment (regardless of reason), <span class="Bold">Table 5</span> presents the proportion of subjects in each study who experienced post-treatment ALT flares. In these studies, a subset of subjects was allowed to discontinue treatment at or after 52 weeks if they achieved a protocol-defined response to therapy. If entecavir is discontinued without regard to treatment response, the rate of post-treatment flares could be higher [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_62bab310-8f05-4b71-b2bc-94fb3aeeff8e">5.1</a>)</span>].</p>
<a name="_RefID6F0162719AA34BC895AB42FDB45C97CF"></a><table width="100%">
<caption><span>Table 5: Exacerbations of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> During Off-Treatment Follow-up, Subjects in Studies AI463022, AI463027, and AI463026 </span></caption>
<col width="27%">
<col width="31%">
<col width="34%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>Reference is the minimum of the baseline or last measurement at end of dosing. Median time to off-treatment exacerbation was 23 weeks for entecavir-treated subjects and 10 weeks for lamivudine-treated subjects.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Subjects with ALT Elevations &gt; 10 x ULN and &gt; 2 x Reference</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Entecavir </span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Lamivudine</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Nucleoside-inhibitor-naÃ¯ve</p></td>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule Rrule"></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"> HBeAg-positive</p></td>
<td class="Botrule Lrule" align="center"><p class="First">4/174 (2%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13/147 (9%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"> HBeAg-negative</p></td>
<td class="Botrule Lrule" align="center"><p class="First">24/302 (8%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">30/270 (11%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Lamivudine-refractory</p></td>
<td class="Botrule Lrule" align="center"><p class="First">6/52 (12%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0/16</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Decompensated Liver Disease</span></p>
<p>Study AI463048 was a randomized, open-label study of entecavir 1 mg once daily versus adefovir dipivoxil 10 mg once daily given for up to 48 weeks in adult subjects with chronic HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and evidence of hepatic decompensation, defined as a Child-Turcotte-Pugh (CTP) score of 7 or higher [<span class="Italics">see Clinical Studies (<a href="#i4i_section_id_77a23d62-e753-42bc-abc8-01ca6ecfeb58">14.1</a>)</span>]. Among the 102 subjects receiving entecavir, the most common treatment-emergent adverse events of any severity, regardless of causality, occurring through Week 48 were <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> (16%), <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span> (15%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span> (14%), <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span> (10%), and <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span> (10%). Clinical adverse reactions not listed in <span class="Bold">Table 2</span> that were observed through Week 48 include blood <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> decreased (2%) and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (&lt; 1%). </p>
<p>Eighteen of 102 (18%) subjects treated with entecavir and 18/89 (20%) subjects treated with adefovir dipivoxil died during the first 48 weeks of therapy. The majority of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> (11 in the entecavir group and 16 in the adefovir dipivoxil group) were due to liver-related causes such as <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="4029488" conceptname="Hepatic encephalopathy">hepatic encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="196455" conceptname="Hepatorenal syndrome">hepatorenal syndrome</span>, and <span class="product-label-link" type="condition" conceptid="4291649" conceptname="Upper gastrointestinal hemorrhage">upper gastrointestinal hemorrhage</span>. The rate of hepatocellular carcinoma (HCC) through Week 48 was 6% (6/102) for subjects treated with entecavir and 8% (7/89) for subjects treated with adefovir dipivoxil. Five percent of subjects in either treatment arm discontinued therapy due to an adverse event through Week 48. </p>
<p>No subject in either treatment arm experienced an on-treatment hepatic flare (ALT &gt; 2 x baseline and &gt; 10 x ULN) through Week 48. Eleven of 102 (11%) subjects treated with entecavir and 11/89 (13%) subjects treated with adefovir dipivoxil had a confirmed increase in serum creatinine of 0.5 mg/dL through Week 48. </p>
<p><span class="Bold">HIV/HBV Co-infected</span></p>
<p>The safety profile of entecavir 1 mg (n = 51) in HIV/HBV co-infected subjects enrolled in Study AI463038 was similar to that of placebo (n = 17) through 24 weeks of blinded treatment and similar to that seen in non-HIV infected subjects [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_4c0e552a-fb83-400d-a62f-52d7ed779778">5.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4245e03a-af9c-4218-aff5-7a9bab9d3cc2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Clinical Trial Experience in Pediatric Subjects</h2>
<p class="First">Pediatric use information is approved for Bristol-Myers Squibb Companyâ€™s Baraclude<span class="Sup">Â®</span> (entecavir) tablets. However, due to Bristol-Myers Squibb Companyâ€™s marketing exclusivity rights, this drug product is not labeled with that information.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_23998615-2372-4f1e-9d96-5a2a7da553fd"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been reported during postmarketing use of entecavir. Because these reactions were reported voluntarily from a population of unknown size, it is not possible to reliably estimate their frequency or establish a causal relationship to entecavir exposure. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span>: </span><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reaction</span>. </p>
<p><span class="Italics">Metabolism and nutrition disorders: </span> <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span>.</p>
<p><span class="Italics">Hepatobiliary disorders: </span>Increased transaminases.</p>
<p><span class="Italics">Skin and subcutaneous tissue disorders: </span><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_a616f445-d0e5-45bf-a84f-7cd583bbca08"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Since entecavir is primarily eliminated by the kidneys [<span class="Italics">see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_d9ded4af-763a-443b-95ae-0db06b88eb97">12.3</a>)</span>], coadministration of entecavir with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug. Coadministration of entecavir with lamivudine, adefovir dipivoxil, or tenofovir disoproxil fumarate did not result in significant drug interactions. The effects of coadministration of entecavir with other drugs that are renally eliminated or are known to affect renal function have not been evaluated, and patients should be monitored closely for adverse events when entecavir is coadministered with such drugs.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_a84288ef-3c9e-4c85-a54c-cf37da5a0e9a"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_2a35919b-eeac-48ef-b652-99ebc79777b1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_5dfa210d-442a-4789-aff2-2a6730e4c9d0"></a><a name="section-8.1.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b2cb72c3-ae43-416b-8b63-85fa976c7741"></a><a name="section-8.1.1.1"></a><p></p>
<h4>Pregnancy category C</h4>
<p class="First">There are no adequate and well-controlled studies of entecavir in pregnant women. Because animal reproduction studies are not always predictive of human response, entecavir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p><span class="Bold">Antiretroviral Pregnancy Registry: </span>To monitor fetal outcomes of pregnant women exposed to entecavir, an <span class="Bold">Antiretroviral Pregnancy Registry</span> has been established. Healthcare providers are encouraged to register patients by calling 1-800-258-4263.</p>
<p><span class="Bold">Animal Data</span></p>
<p>Animal reproduction studies with entecavir in rats and rabbits revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. Developmental toxicity studies were performed in rats and rabbits. There were no signs of embryofetal or maternal toxicity when pregnant animals received oral entecavir at approximately 28 (rat) and 212 (rabbit) times the human exposure achieved at the highest recommended human dose of 1 mg/day. In rats, maternal toxicity, embryofetal toxicity (resorptions), lower fetal body weights, tail and vertebral malformations, reduced ossification (vertebrae, sternebrae, and phalanges), and extra lumbar vertebrae and ribs were observed at exposures 3100 times those in humans. In rabbits, embryofetal toxicity (resorptions), reduced ossification (hyoid), and an increased incidence of 13<span class="Sup">th</span> rib were observed at exposures 883 times those in humans. In a peri-postnatal study, no adverse effects on offspring occurred when rats received oral entecavir at exposures greater than 94 times those in humans.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_0269a57c-91e9-4fcd-ae2d-074332bf2710"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">There are no studies in pregnant women and no data on the effect of entecavir on transmission of HBV from mother to infant. Therefore, appropriate interventions should be used to prevent neonatal acquisition of HBV.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_205fe8fe-e505-4191-bd2e-65ead379e69e"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether entecavir is excreted into human milk; however, entecavir is excreted into the milk of rats. Because many drugs are excreted into human milk and because of the potential for serious adverse reactions in nursing infants from entecavir, a decision should be made to discontinue nursing or to discontinue entecavir taking into consideration the importance of continued <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B therapy to the mother and the known benefits of breastfeeding.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_ebf88d72-5426-4440-b8dc-708a18e71ecd"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The efficacy and safety of entecavir has not been established in patients less than 2 years of age. Use of entecavir in this age group has not been evaluated because treatment of HBV in this age group is rarely required. <br><br>Pediatric use information is approved for Bristol-Myers Squibb Companyâ€™s Baraclude<span class="Sup">Â®</span> (entecavir) tablets. However, due to Bristol-Myers Squibb Companyâ€™s marketing exclusivity rights, this drug product is not labeled with that information.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_90a66ff0-0e81-41af-a69b-417de6a57f13"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of entecavir did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. Entecavir is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_a0f488ba-5707-49e4-a065-03339b0a30c6">2.4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_077a3a85-70f6-41d1-ae00-25e4284b14ce"></a><a name="section-8.6"></a><p></p>
<h2>8.6 Racial/Ethnic Groups</h2>
<p class="First">There are no significant racial differences in entecavir pharmacokinetics. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_be70f6ef-af1d-4bd9-ba18-c7539125563b"></a><a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Dosage adjustment of entecavir is recommended for patients with creatinine clearance less than 50 mL/min, including patients on hemodialysis or CAPD [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_a0f488ba-5707-49e4-a065-03339b0a30c6">2.4</a>) and Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_d9ded4af-763a-443b-95ae-0db06b88eb97">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cd43ac2f-9bd8-4a96-8a9c-f6034ab31f44"></a><a name="section-8.8"></a><p></p>
<h2>8.8 Liver Transplant Recipients </h2>
<p class="First">If entecavir treatment is determined to be necessary for a liver transplant recipient who has received or is receiving an immunosuppressant that may affect renal function, such as cyclosporine or tacrolimus, renal function must be carefully monitored both before and during treatment with entecavir [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_a0f488ba-5707-49e4-a065-03339b0a30c6">2.4</a>) and Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_d9ded4af-763a-443b-95ae-0db06b88eb97">12.3</a>)</span>]. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_1e1711ce-36cf-44d3-9c1e-b229c094b802"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is limited experience of entecavir overdosage reported in patients. Healthy subjects who received single entecavir doses up to 40 mg or multiple doses up to 20 mg/day for up to 14 days had no increase in or unexpected adverse events. If <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> occurs, the patient must be monitored for evidence of toxicity, and standard supportive treatment applied as necessary.</p>
<p>Following a single 1 mg dose of entecavir, a 4 hour hemodialysis session removed approximately 13% of the entecavir dose.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_3aed140d-30f0-4764-8797-90a22348aef4"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Entecavir is a guanosine nucleoside analogue with selective activity against HBV. The chemical name for entecavir is 2-amino-1,9-dihydro-9-[(<span class="Italics">1S, 3R, 4S</span>)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6<span class="Italics">H</span>-purin-6-one, monohydrate. Entecavir has the following structural formula:</p>
<div class="Figure">
<a name="id1201704912"></a><img alt="Structural formula.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e527b81a-5e15-4b58-91ed-3df45f3ac589&amp;name=image-01.jpg">
</div>
<p>                                                         C<span class="Sub">12</span>H<span class="Sub">15</span>N<span class="Sub">5</span>O<span class="Sub">3</span>â€¢H<span class="Sub">2</span>O                                        M.W. 295.3 </p>
<p>Entecavir monohydrate is a white to off-white crystalline powder. It is slightly soluble in water (2.4 mg/mL), and the pH of the saturated solution in water is 7.9 at 25Â° C Â± 0.5Â° C.</p>
<p>Each film-coated tablet, for oral administration, contains either 0.533 mg or 1.066 mg of entecavir monohydrate, equivalent to 0.5 mg or 1 mg of entecavir. In addition, each film-coated tablet contains the following inactive ingredients: crospovidone, magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, pregelatinized starch, talc, and titanium dioxide. In addition, the 1 mg contains FD&amp;C blue #2 aluminum lake, FD&amp;C red #40 aluminum lake, and iron oxide yellow. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_1339071b-8f06-4d37-8087-397525b8b04e"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_54147072-a874-4de7-87e3-0a386c875f74"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Entecavir is an antiviral drug [<span class="Italics">see Microbiology (<a href="#i4i_microbiology_id_cd45fa9a-4e9c-4d8e-9233-545dc108015d">12.4</a>)</span>]<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_d9ded4af-763a-443b-95ae-0db06b88eb97"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The single- and multiple-dose pharmacokinetics of entecavir were evaluated in healthy subjects and subjects with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p><span class="Bold">Absorption</span></p>
<p>Following oral administration in healthy subjects, entecavir peak plasma concentrations occurred between 0.5 and 1.5 hours. Following multiple daily doses ranging from 0.1 to 1 mg, C<span class="Sub">max</span> and area under the concentration-time curve (AUC) at steady state increased in proportion to dose. Steady state was achieved after 6 to 10 days of once-daily administration with approximately 2 fold accumulation. For a 0.5 mg oral dose, C<span class="Sub">max</span> at steady state was 4.2 ng/mL and trough plasma concentration (C<span class="Sub">trough</span>) was 0.3 ng/mL. For a 1 mg oral dose, C<span class="Sub">max</span> was 8.2 ng/mL and C<span class="Sub">trough</span> was 0.5 ng/mL.</p>
<p><span class="Italics">Effects of food on oral absorption: </span>Oral administration of 0.5 mg of entecavir with a standard high-fat meal (945 kcal, 54.6 g fat) or a light meal (379 kcal, 8.2 g fat) resulted in a delay in absorption (1.0 to 1.5 hours fed vs. 0.75 hours fasted), a decrease in C<span class="Sub">max</span> of 44% to 46%, and a decrease in AUC of 18% to 20% [<span class="Italics">see Dosage and Administration (<a href="#i4i_dosage_admin_id_8e1d9cb2-f0f8-45b6-b841-7e5ce02be893">2</a>)</span>].</p>
<p><span class="Bold">Distribution</span></p>
<p>Based on the pharmacokinetic profile of entecavir after oral dosing, the estimated apparent volume of distribution is in excess of total body water, suggesting that entecavir is extensively distributed into tissues.</p>
<p>Binding of entecavir to human serum proteins <span class="Italics">in vitro </span>was approximately 13%.</p>
<p><span class="Bold">Metabolism and Elimination</span></p>
<p>Following administration of <span class="Sup">14</span>C-entecavir in humans and rats, no oxidative or acetylated metabolites were observed. Minor amounts of phase II metabolites (glucuronide and sulfate conjugates) were observed. Entecavir is not a substrate, inhibitor, or inducer of the cytochrome P450 (CYP450) enzyme system. <span class="Italics">See Drug Interactions, below</span>.</p>
<p>After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128 to 149 hours. The observed drug accumulation index is approximately 2 fold with once-daily dosing, suggesting an effective accumulation half-life of approximately 24 hours.</p>
<p>Entecavir is predominantly eliminated by the kidney with urinary recovery of unchanged drug at steady state ranging from 62% to 73% of the administered dose. Renal clearance is independent of dose and ranges from 360 to 471 mL/min suggesting that entecavir undergoes both glomerular filtration and net tubular secretion [<span class="Italics">see Drug Interactions (<a href="#i4i_interactions_id_a616f445-d0e5-45bf-a84f-7cd583bbca08">7</a>)</span>].</p>
<p><span class="Bold">Special Populations</span></p>
<p><span class="Italics">Gender: </span>There are no significant gender differences in entecavir pharmacokinetics.</p>
<p><span class="Italics">Race: </span>There are no significant racial differences in entecavir pharmacokinetics.</p>
<p><span class="Italics">Elderly: </span>The effect of age on the pharmacokinetics of entecavir was evaluated following administration of a single 1 mg oral dose in healthy young and elderly volunteers. Entecavir AUC was 29.3% greater in elderly subjects compared to young subjects. The disparity in exposure between elderly and young subjects was most likely attributable to differences in renal function. Dosage adjustment of entecavir should be based on the renal function of the patient, rather than age [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_a0f488ba-5707-49e4-a065-03339b0a30c6">2.4</a>)</span>].</p>
<p><span class="Italics">Pediatrics: </span></p>
<p>Pediatric use information is approved for Bristol-Myers Squibb Companyâ€™s Baraclude<span class="Sup">Â®</span> (entecavir) tablets. However, due to Bristol-Myers Squibb Companyâ€™s marketing exclusivity rights, this drug product is not labeled with that information.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: </span>The pharmacokinetics of entecavir following a single 1 mg dose were studied in subjects (without <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>) with selected degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, including subjects whose <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> was managed by hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). Results are shown in <span class="Bold">Table 7</span> [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_a0f488ba-5707-49e4-a065-03339b0a30c6">2.4</a>)</span>].</p>
<a name="_RefID504A5FCF88314909962428341DF6555B"></a><table width="100%">
<caption><span>Table 7: Pharmacokinetic Parameters in Subjects With Selected Degrees of Renal Function  </span></caption>
<col width="22%">
<col width="17%">
<col width="12%">
<col width="10%">
<col width="8%">
<col width="19%">
<col width="12%">
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-12" href="#footnote-reference-12">*</a></dt>
<dd>Dosed immediately following hemodialysis.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Botrule Toprule" align="center" colspan="6"><p class="First"><span class="Bold">Renal Function Group</span></p></td>
</tr>
<tr>
<td></td>
<td class="Botrule" align="center" colspan="4"><p class="First"><span class="Bold">Baseline Creatinine Clearance (mL/min)</span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td class="Botrule"></td>
<td class="Botrule" align="center">
<p class="First"><span class="Bold">Unimpaired &gt; 80</span></p>
<p><br><span class="Bold">n = 6</span></p>
</td>
<td class="Botrule" align="center">
<p class="First"><span class="Bold">Mild</span><br><span class="Bold">&gt; 50 to â‰¤ 80</span></p>
<p><span class="Bold">n = 6</span></p>
</td>
<td class="Botrule" align="center">
<p class="First"><span class="Bold">Moderate</span><br><span class="Bold">30 to 50</span></p>
<p><span class="Bold">n = 6</span></p>
</td>
<td class="Botrule" align="center">
<p class="First"><span class="Bold">Severe</span></p>
<p><span class="Bold">&lt; 30</span></p>
<p><span class="Bold">n = 6</span></p>
</td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Severe</span><br><span class="Bold">Managed with</span><br><span class="Bold">Hemodialysis</span><a name="footnote-reference-12" href="#footnote-12" class="Sup">*</a><span class="Bold"> n = 6</span></p></td>
<td class="Botrule">
<p class="First"><span class="Bold">Severe</span><br><span class="Bold">Managed</span></p>
<p><span class="Bold">with CAPD</span></p>
<p><span class="Bold">n = 4</span></p>
</td>
</tr>
<tr>
<td><p class="First">C<span class="Sub">max</span> (ng/mL)<br>(CV%)</p></td>
<td align="center"><p class="First">8.1<br>(30.7)</p></td>
<td align="center"><p class="First">10.4 <br>(37.2)</p></td>
<td align="center"><p class="First">10.5<br>(22.7)</p></td>
<td align="center"><p class="First">15.3<br>(33.8)</p></td>
<td align="center"><p class="First">15.4<br>(56.4)</p></td>
<td align="center"><p class="First">16.6<br>(29.7)</p></td>
</tr>
<tr>
<td><p class="First">AUC<span class="Sub">(0-T) </span>(ngâ€¢h/mL) (CV)</p></td>
<td align="center"><p class="First">27.9<br>(25.6)</p></td>
<td align="center"><p class="First">51.5 <br>(22.8)</p></td>
<td align="center"><p class="First">69.5<br>(22.7)</p></td>
<td align="center"><p class="First">145.7<br>(31.5)</p></td>
<td align="center"><p class="First">233.9<br>(28.4)</p></td>
<td align="center"><p class="First">221.8<br>(11.6)</p></td>
</tr>
<tr>
<td>
<p class="First">CLR (mL/min) </p>
<p>(SD)</p>
</td>
<td align="center"><p class="First">383.2<br>(101.8)</p></td>
<td align="center"><p class="First">197.9<br>(78.1)</p></td>
<td align="center"><p class="First">135.6<br>(31.6)</p></td>
<td align="center"><p class="First">40.3<br>(10.1)</p></td>
<td align="center"><p class="First">NA</p></td>
<td align="center"><p class="First">NA</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">CLT/F (mL/min) (SD)</p></td>
<td class="Botrule" align="center"><p class="First">588.1<br>(153.7)</p></td>
<td class="Botrule" align="center"><p class="First">309.2<br>(62.6)</p></td>
<td class="Botrule" align="center"><p class="First">226.3<br>(60.1)</p></td>
<td class="Botrule" align="center"><p class="First">100.6<br>(29.1)</p></td>
<td class="Botrule" align="center"><p class="First">50.6<br>(16.5)</p></td>
<td class="Botrule" align="center"><p class="First">35.7<br>(19.6)</p></td>
</tr>
</tbody>
</table>
<p>CLR = renal clearance; CLT/F = apparent oral clearance.</p>
<p>Following a single 1 mg dose of entecavir administered 2 hours before the hemodialysis session, hemodialysis removed approximately 13% of the entecavir dose over 4 hours. CAPD removed approximately 0.3% of the dose over 7 days [<span class="Italics">see Dosage and Administration (<a href="#i4i_section_id_a0f488ba-5707-49e4-a065-03339b0a30c6">2.4</a>)</span>].</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>: </span>The pharmacokinetics of entecavir following a single 1 mg dose were studied in adult subjects (without <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>) with moderate or severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Turcotte-Pugh Class B or C). The pharmacokinetics of entecavir were similar between hepatically impaired and healthy control subjects; therefore, no dosage adjustment of entecavir is recommended for patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. The pharmacokinetics of entecavir have not been studied in pediatric subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p><span class="Italics">Post-liver transplant: </span>Limited data are available on the safety and efficacy of entecavir in liver transplant recipients. In a small pilot study of entecavir use in HBV-infected liver transplant recipients on a stable dose of cyclosporine A (n = 5) or tacrolimus (n = 4), entecavir exposure was approximately 2 fold the exposure in healthy subjects with normal renal function. Altered renal function contributed to the increase in entecavir exposure in these subjects. The potential for <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> between entecavir and cyclosporine A or tacrolimus was not formally evaluated [<span class="Italics">see Use in Specific Populations (<a href="#i4i_section_id_cd43ac2f-9bd8-4a96-8a9c-f6034ab31f44">8.8</a>)</span>].</p>
<p><span class="Bold">Drug Interactions</span></p>
<p>The metabolism of entecavir was evaluated in <span class="Italics">in vitro </span>and <span class="Italics">in vivo </span>studies. Entecavir is not a substrate, inhibitor, or inducer of the cytochrome P450 (CYP450) enzyme system. At concentrations up to approximately 10,000 fold higher than those obtained in humans, entecavir inhibited none of the major human CYP450 enzymes 1A2, 2C9, 2C19, 2D6, 3A4, 2B6, and 2E1. At concentrations up to approximately 340 fold higher than those observed in humans, entecavir did not induce the human CYP450 enzymes 1A2, 2C9, 2C19, 3A4, 3A5, and 2B6. The pharmacokinetics of entecavir are unlikely to be affected by coadministration with agents that are either metabolized by, inhibit, or induce the CYP450 system. Likewise, the pharmacokinetics of known CYP substrates are unlikely to be affected by coadministration of entecavir.</p>
<p>The steady-state pharmacokinetics of entecavir and coadministered drug were not altered in interaction studies of entecavir with lamivudine, adefovir dipivoxil, and tenofovir disoproxil fumarate [<span class="Italics">see Drug Interactions (<a href="#i4i_interactions_id_a616f445-d0e5-45bf-a84f-7cd583bbca08">7</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_microbiology_id_cd45fa9a-4e9c-4d8e-9233-545dc108015d"></a><a name="section-11.3"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First"><span class="Bold">Mechanism of Action</span></p>
<p>Entecavir, a guanosine nucleoside analogue with activity against HBV reverse transcriptase (rt), is efficiently phosphorylated to the active triphosphate form, which has an intracellular half-life of 15 hours. By competing with the natural substrate deoxyguanosine triphosphate, entecavir triphosphate functionally inhibits all three activities of the HBV reverse transcriptase: (1) base priming, (2) reverse transcription of the negative strand from the pregenomic messenger RNA, and (3) synthesis of the positive strand of HBV DNA. Entecavir triphosphate is a weak inhibitor of cellular DNA polymerases Î±, Î², and Î´ and mitochondrial DNA polymerase Î³ with K<span class="Sub">i </span>values ranging from 18 to &gt; 160 ÂµM.</p>
<p><span class="Bold">Antiviral Activity</span></p>
<p>Entecavir inhibited HBV DNA synthesis (50% reduction, EC<span class="Sub">50</span>) at a concentration of 0.004 ÂµM in human HepG2 cells transfected with wild-type HBV. The median EC<span class="Sub">50</span> value for entecavir against lamivudine-resistant HBV (rtL180M, rtM204V) was 0.026 ÂµM (range 0.010 to 0.059 ÂµM).</p>
<p>The coadministration of HIV nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) with entecavir is unlikely to reduce the antiviral efficacy of entecavir against HBV or of any of these agents against HIV. In HBV combination assays in cell culture, abacavir, didanosine, lamivudine, stavudine, tenofovir, or zidovudine were not antagonistic to the anti-HBV activity of entecavir over a wide range of concentrations. In HIV antiviral assays, entecavir was not antagonistic to the cell culture anti-HIV activity of these six NRTIs or emtricitabine at concentrations greater than 100 times the C<span class="Sub">max</span> of entecavir using the 1 mg dose.</p>
<p><span class="Bold"><span class="Italics">Antiviral Activity Against HIV</span></span></p>
<p>A comprehensive analysis of the inhibitory activity of entecavir against a panel of laboratory and clinical HIV type 1 (HIV-1) isolates using a variety of cells and assay conditions yielded EC<span class="Sub">50</span> values ranging from 0.026 to &gt; 10 ÂµM; the lower EC<span class="Sub">50</span> values were observed when decreased levels of virus were used in the assay. In cell culture, entecavir selected for an M184I substitution in HIV reverse transcriptase at micromolar concentrations, confirming inhibitory pressure at high entecavir concentrations. HIV variants containing the M184V substitution showed loss of susceptibility to entecavir.</p>
<p><span class="Bold">Resistance </span></p>
<p><span class="Bold"><span class="Italics">In Cell Culture</span></span></p>
<p>In cell-based assays, 8 to 30 fold reductions in entecavir phenotypic susceptibility were observed for lamivudine-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>. Further reductions (&gt; 70 fold) in entecavir phenotypic susceptibility required the presence of amino acid substitutions rtM204I/V with or without rtL180M along with additional substitutions at residues rtT184, rtS202, or rtM250, or a combination of these substitutions with or without an rtI169 substitution in the HBV reverse transcriptase.</p>
<p><span class="Bold"><span class="Italics">Clinical Studies</span></span></p>
<p><span class="Italics">Nucleoside-inhibitor-naÃ¯ve subjects</span>: Genotypic evaluations were performed on evaluable samples (&gt; 300 copies/mL serum HBV DNA) from 562 subjects who were treated with entecavir for up to 96 weeks in nucleoside-inhibitor-naÃ¯ve studies (AI463022, AI463027, and rollover study AI463901). By Week 96, evidence of emerging amino acid substitution rtS202G with rtM204V and rtL180M substitutions was detected in the HBV of 2 subjects (2/562 = &lt; 1%), and 1 of them experienced virologic rebound (â‰¥ 1 log<span class="Sub">10</span> increase above nadir). In addition, emerging amino acid substitutions at rtM204I/V and rtL180M, rtL80I, or rtV173L, which conferred decreased phenotypic susceptibility to entecavir in the absence of rtT184, rtS202, or rtM250 changes, were detected in the HBV of 3 subjects (3/562 = &lt; 1%) who experienced virologic rebound. For subjects who continued treatment beyond 48 weeks, 75% (202/269) had HBV DNA &lt; 300 copies/mL at end of dosing (up to 96 weeks). </p>
<p>HBeAg-positive (n = 243) and -negative (n = 39) treatment-naÃ¯ve subjects who failed to achieve the study-defined complete response by 96 weeks were offered continued entecavir treatment in a rollover study. Complete response for HBeAg-positive was &lt; 0.7 MEq/mL (approximately 7 x 10<span class="Sup">5 </span>copies/mL) serum HBV DNA and HBeAg loss and, for HBeAg-negative was &lt; 0.7 MEq/mL HBV DNA and ALT normalization. Subjects received 1 mg entecavir once daily for up to an additional 144 weeks. Of these 282 subjects, 141 HBeAg-positive and 8 HBeAg-negative subjects entered the long-term follow-up rollover study and were evaluated for entecavir resistance. Of the 149 subjects entering the rollover study, 88% (131/149), 92% (137/149), and 92% (137/149) attained serum HBV DNA &lt; 300 copies/mL by Weeks 144, 192, and 240 (including end of dosing), respectively. No novel entecavir resistance-associated substitutions were identified in a comparison of the genotypes of evaluable isolates with their respective baseline isolates. The cumulative probability of developing rtT184, rtS202, or rtM250 entecavir resistance-associated substitutions (in the presence of rtM204V and rtL180M substitutions) at Weeks 48, 96, 144, 192, and 240 was 0.2%, 0.5%, 1.2%, 1.2%, and 1.2%, respectively.</p>
<p><span class="Italics">Lamivudine-refractory subjects: </span>Genotypic evaluations were performed on evaluable samples from 190 subjects treated with entecavir for up to 96 weeks in studies of lamivudine-refractory HBV (AI463026, AI463014, AI463015, and rollover study AI463901). By Week 96, resistance-associated amino acid substitutions at rtS202, rtT184, or rtM250, with or without rtI169 changes, in the presence of amino acid substitutions rtM204I/V with or without rtL180M, rtL80V, or rtV173L/M emerged in the HBV from 22 subjects (22/190 = 12%), 16 of whom experienced virologic rebound (â‰¥ 1 log<span class="Sub">10</span> increase above nadir) and 4 of whom were never suppressed &lt; 300 copies/mL. The HBV from 4 of these subjects had entecavir resistance substitutions at baseline and acquired further changes on entecavir treatment. In addition to the 22 subjects, 3 subjects experienced virologic rebound with the emergence of rtM204I/V and rtL180M, rtL80V, or rtV173L/M. For isolates from subjects who experienced virologic rebound with the emergence of resistance substitutions (n = 19), the median fold-change in entecavir EC<span class="Sub">50</span> values from reference was 19 fold at baseline and 106 fold at the time of virologic rebound. For subjects who continued treatment beyond 48 weeks, 40% (31/77) had HBV DNA &lt; 300 copies/mL at end of dosing (up to 96 weeks).</p>
<p>Lamivudine-refractory subjects (n = 157) who failed to achieve the study-defined complete response by Week 96 were offered continued entecavir treatment. Subjects received 1 mg entecavir once daily for up to an additional 144 weeks. Of these subjects, 80 subjects entered the long-term follow-up study and were evaluated for entecavir resistance. By Weeks 144, 192, and 240 (including end of dosing), 34% (27/80), 35% (28/80), and 36% (29/80), respectively, attained HBV DNA &lt; 300 copies/mL. The cumulative probability of developing rtT184, rtS202, or rtM250 entecavir-resistance associated substitutions (in the presence of rtM204I/V with or without rtL180M substitutions) at Weeks 48, 96, 144, 192, and 240 was 6.2%, 15%, 36.3%, 46.6%, and 51.5%, respectively. The HBV of 6 subjects developed rtA181C/G/S/T amino acid substitutions while receiving entecavir, and of these, 4 developed entecavir resistance-associated substitutions at rtT184, rtS202, or rtM250 and 1 had an rtT184S substitution at baseline. Of 7 subjects whose HBV had an rtA181 substitution at baseline, 2 also had substitutions at rtT184, rtS202, or rtM250 at baseline and another 2 developed them while on treatment with entecavir.</p>
<p><span class="Bold"><span class="Italics">Cross-resistance</span></span></p>
<p>Cross-resistance has been observed among HBV nucleoside analogue inhibitors. In cell-based assays, entecavir had 8 to 30 fold less inhibition of HBV DNA synthesis for HBV containing lamivudine and telbivudine resistance substitutions rtM204I/V with or without rtL180M than for wild-type HBV. Substitutions rtM204I/V with or without rtL180M, rtL80I/V, or rtV173L, which are associated with lamivudine and telbivudine resistance, also confer decreased phenotypic susceptibility to entecavir. The efficacy of entecavir against HBV harboring adefovir resistance- associated substitutions has not been established in clinical trials. HBV isolates from lamivudine-refractory subjects failing entecavir therapy were susceptible in cell culture to adefovir but remained resistant to lamivudine. Recombinant HBV genomes encoding adefovir resistance-associated substitutions at either rtN236T or rtA181V had 0.3 and 1.1 fold shifts in susceptibility to entecavir in cell culture, respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_bfe15298-b36c-443b-812f-cb3151f9c44c"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_13486168-cecd-4b6a-8629-ae5bd8961f99"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Bold">Carcinogenesis</span></p>
<p>Long-term oral carcinogenicity studies of entecavir in mice and rats were carried out at exposures up to approximately 42 times (mice) and 35 times (rats) those observed in humans at the highest recommended dose of 1 mg/day. In mouse and rat studies, entecavir was positive for carcinogenic findings.</p>
<p>In mice, lung <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> were increased in males and females at exposures 3 and 40 times those in humans. Lung carcinomas in both male and female mice were increased at exposures 40 times those in humans. Combined lung <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and carcinomas were increased in male mice at exposures 3 times and in female mice at exposures 40 times those in humans. Tumor development was preceded by pneumocyte proliferation in the lung, which was not observed in rats, dogs, or monkeys administered entecavir, supporting the conclusion that lung tumors in mice may be a species-specific event. Hepatocellular carcinomas were increased in males and combined liver <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and carcinomas were also increased at exposures 42 times those in humans. Vascular tumors in female mice (<span class="product-label-link" type="condition" conceptid="441818" conceptname="Hemangioma">hemangiomas</span> of ovaries and uterus and <span class="product-label-link" type="condition" conceptid="4297200" conceptname="Angiosarcoma">hemangiosarcomas</span> of spleen) were increased at exposures 40 times those in humans. In rats, <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> were increased in females at exposures 24 times those in humans; combined <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span> and carcinomas were also increased in females at exposures 24 times those in humans. Brain <span class="product-label-link" type="condition" conceptid="4019491" conceptname="Glioma">gliomas</span> were induced in both males and females at exposures 35 and 24 times those in humans. Skin <span class="product-label-link" type="condition" conceptid="4012174" conceptname="Fibroma">fibromas</span> were induced in females at exposures 4 times those in humans.</p>
<p>It is not known how predictive the results of rodent carcinogenicity studies may be for humans.</p>
<p><span class="Bold">Mutagenesis</span></p>
<p>Entecavir was clastogenic to human lymphocyte cultures. Entecavir was not mutagenic in the Ames bacterial reverse mutation assay using <span class="Italics">S. typhimurium </span>and <span class="Italics">E. coli </span><span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> in the presence or absence of metabolic activation, a mammalian-cell gene mutation assay, and a transformation assay with Syrian hamster embryo cells. Entecavir was also negative in an oral micronucleus study and an oral DNA repair study in rats. </p>
<p><span class="Bold">Impairment of Fertility</span></p>
<p>In reproductive toxicology studies, in which animals were administered entecavir at up to 30 mg/kg for up to 4 weeks, no evidence of impaired fertility was seen in male or female rats at systemic exposures greater than 90 times those achieved in humans at the highest recommended dose of 1 mg/day. In rodent and dog toxicology studies, seminiferous tubular degeneration was observed at exposures 35 times or greater than those achieved in humans. No testicular changes were evident in monkeys.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_8013f147-aef5-4212-b2b8-c76be2f19f7c"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_77a23d62-e753-42bc-abc8-01ca6ecfeb58"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Outcomes in Adults</h2>
<p class="First"><span class="Bold">At 48 Weeks</span></p>
<p>The safety and efficacy of entecavir in adults were evaluated in three Phase 3 active-controlled trials. These studies included 1633 subjects 16 years of age or older with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (serum HBsAg-positive for at least 6 months) accompanied by evidence of viral replication (detectable serum HBV DNA, as measured by the bDNA hybridization or PCR assay). Subjects had persistently elevated ALT levels at least 1.3 times ULN and chronic <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> on liver biopsy compatible with a diagnosis of chronic <span class="product-label-link" type="condition" conceptid="4291005" conceptname="Viral hepatitis">viral hepatitis</span>. The safety and efficacy of entecavir were also evaluated in a study of 191 HBV-infected subjects with decompensated liver disease and in a study of 68 subjects co-infected with HBV and HIV.</p>
<p><span class="Bold"><span class="Italics">Nucleoside-inhibitor-naÃ¯ve Subjects with Compensated Liver Disease</span></span></p>
<p><span class="Italics">HBeAg-positive: </span>Study AI463022 was a multinational, randomized, double-blind study of entecavir 0.5 mg once daily versus lamivudine 100 mg once daily for a minimum of 52 weeks in 709 (of 715 randomized) nucleoside-inhibitor-naÃ¯ve subjects with <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, compensated liver disease, and detectable HBeAg. The mean age of subjects was 35 years, 75% were male, 57% were Asian, 40% were Caucasian, and 13% had previously received interferon-Î±. At baseline, subjects had a mean Knodell Necroinflammatory Score of 7.8, mean serum HBV DNA as measured by Roche COBAS Amplicor<span class="Sup">Â®</span> PCR assay was 9.66 log<span class="Sub">10</span> copies/mL, and mean serum ALT level was 143 U/L. Paired, adequate liver biopsy samples were available for 89% of subjects.</p>
<p><span class="Italics">HBeAg-negative (anti-HBe-positive/HBV DNA-positive): </span>Study AI463027 was a multinational, randomized, double-blind study of entecavir 0.5 mg once daily versus lamivudine 100 mg once daily for a minimum of 52 weeks in 638 (of 648 randomized) nucleoside-inhibitor-naÃ¯ve subjects with HBeAg-negative (HBeAb-positive) <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and compensated liver disease. The mean age of subjects was 44 years, 76% were male, 39% were Asian, 58% were Caucasian, and 13% had previously received interferon-Î±. At baseline, subjects had a mean Knodell Necroinflammatory Score of 7.8, mean serum HBV DNA as measured by Roche COBAS Amplicor PCR assay was 7.58 log<span class="Sub">10</span> copies/mL, and mean serum ALT level was 142 U/L. Paired, adequate liver biopsy samples were available for 88% of subjects.</p>
<p>In Studies AI463022 and AI463027, entecavir was superior to lamivudine on the primary efficacy endpoint of Histologic Improvement, defined as a 2 point or greater reduction in Knodell Necroinflammatory Score with no worsening in Knodell <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">Fibrosis</span> Score at Week 48, and on the secondary efficacy measures of reduction in viral load and ALT normalization. Histologic Improvement and change in Ishak <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">Fibrosis</span> Score are shown in <span class="Bold">Table 8</span>. Selected virologic, biochemical, and serologic outcome measures are shown in <span class="Bold">Table 9</span>.</p>
<a name="_RefIDC36EC853605148DBB3C884458A9BBC26"></a><table width="100%">
<caption><span>Table 8: Histologic Improvement and Change in Ishak <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">Fibrosis</span> Score at Week 48, Nucleoside-Inhibitor-NaÃ¯ve Subjects in Studies AI463022 and AI463027 </span></caption>
<col width="25%">
<col width="16%">
<col width="20%">
<col width="17%">
<col width="20%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
<dd>Subjects with evaluable baseline histology (baseline Knodell Necroinflammatory Score â‰¥ 2).</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">â€ </a></dt>
<dd>â‰¥ 2 point decrease in Knodell Necroinflammatory Score from baseline with no worsening of the Knodell <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">Fibrosis</span> Score.</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">â€¡</a></dt>
<dd>For Ishak <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">Fibrosis</span> Score, improvement = â‰¥ 1 point decrease from baseline and worsening = â‰¥ 1 point increase from baseline.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Botrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Study AI463022 (HBeAg-Positive)</span></p></td>
<td class="Botrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Study AI463027 (HBeAg-Negative)</span></p></td>
</tr>
<tr>
<td class="Botrule"></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Entecavir </span><br><span class="Bold">0.5 mg</span><br><span class="Bold">n = 314</span><a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a><span class="Bold">Â </span></p></td>
<td class="Botrule" align="center">
<p class="First"><span class="Bold">Lamivudine </span></p>
<p><span class="Bold">100 mg</span></p>
<p><span class="Bold">n = 314</span><a href="#footnote-13" class="Sup">*</a></p>
</td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">Entecavir </span><br><span class="Bold">0.5 mg</span><br><span class="Bold">n = 296</span><a href="#footnote-13" class="Sup">*</a></p></td>
<td class="Botrule" align="center">
<p class="First"><span class="Bold">Lamivudine </span></p>
<p><span class="Bold">100 mg</span></p>
<p><span class="Bold">n = 287</span><a href="#footnote-13" class="Sup">*</a></p>
</td>
</tr>
<tr><td colspan="5"><p class="First"><span class="Bold">Histologic Improvement (Knodell Scores)</span></p></td></tr>
<tr>
<td><p class="First">Improvement<a name="footnote-reference-14" href="#footnote-14" class="Sup">â€ </a></p></td>
<td align="center"><p class="First">72%</p></td>
<td align="center"><p class="First">62%</p></td>
<td align="center"><p class="First">70%</p></td>
<td align="center"><p class="First">61%</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">No improvement</p></td>
<td class="Botrule" align="center"><p class="First">21%</p></td>
<td class="Botrule" align="center"><p class="First">24%</p></td>
<td class="Botrule" align="center"><p class="First">19%</p></td>
<td class="Botrule" align="center"><p class="First">26%</p></td>
</tr>
<tr><td colspan="5"><p class="First"><span class="Bold">Ishak <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">Fibrosis</span> Score</span></p></td></tr>
<tr>
<td><p class="First">Improvement<a name="footnote-reference-15" href="#footnote-15" class="Sup">â€¡</a></p></td>
<td align="center"><p class="First">39%</p></td>
<td align="center"><p class="First">35%</p></td>
<td align="center"><p class="First">36%</p></td>
<td align="center"><p class="First">38%</p></td>
</tr>
<tr>
<td><p class="First">No change</p></td>
<td align="center"><p class="First">46%</p></td>
<td align="center"><p class="First">40%</p></td>
<td align="center"><p class="First">41%</p></td>
<td align="center"><p class="First">34%</p></td>
</tr>
<tr>
<td class="Botrule"><p class="First">Worsening<a href="#footnote-15" class="Sup">â€¡</a></p></td>
<td class="Botrule" align="center"><p class="First">8%</p></td>
<td class="Botrule" align="center"><p class="First">10%</p></td>
<td class="Botrule" align="center"><p class="First">12%</p></td>
<td class="Botrule" align="center"><p class="First">15%</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">Missing Week 48 biopsy</p></td>
<td class="Botrule" align="center"><p class="First">7%</p></td>
<td class="Botrule" align="center"><p class="First">14%</p></td>
<td class="Botrule" align="center"><p class="First">10%</p></td>
<td class="Botrule" align="center"><p class="First">13%</p></td>
</tr>
</tbody>
</table>
<a name="_RefID755C77EBD2D84E9BA9B118F1A7B60FEF"></a><table width="100%">
<caption><span>Table 9: Selected Virologic, Biochemical, and Serologic Endpoints at Week 48, Nucleoside-Inhibitor-NaÃ¯ve Subjects in Studies AI463022 and AI463027 </span></caption>
<col width="27%">
<col width="12%">
<col width="14%">
<col width="12%">
<col width="14%">
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-16" href="#footnote-reference-16">*</a></dt>
<dd>Roche COBAS Amplicor PCR assay [lower limit of quantification (LLOQ) = 300 copies/mL].</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Study AI463022</span><br><span class="Bold">(HBeAg-Positive)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">Study AI463027</span><br><span class="Bold">(HBeAg-Negative)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule"></td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Entecavir </span><br><span class="Bold">0.5 mg</span></p>
<p><span class="Bold">n = 354</span></p>
</td>
<td class="Botrule Lrule" align="center"><p class="First"><span class="Bold">Lamivudine</span><br><span class="Bold">100 mg</span><br><span class="Bold">n = 355</span></p></td>
<td class="Botrule Lrule" align="center">
<p class="First"><span class="Bold">Entecavir</span><br><span class="Bold">0.5 mg</span></p>
<p><span class="Bold">n = 325</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Lamivudine</span><br><span class="Bold">100 mg</span><br><span class="Bold">n = 313</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="5"><p class="First">HBV DNA<a name="footnote-reference-16" href="#footnote-16" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"> Proportion undetectable <br> (&lt; 300 copies/mL)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">67%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">36%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">90%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">72%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"> Mean change from <br> baseline (log<span class="Sub">10 </span>copies/mL)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-6.86</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-5.39</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-5.04</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-4.53</p></td>
</tr>
<tr>
<td class="Botrule Lrule">
<p class="First">ALT normalization </p>
<p>(â‰¤ 1 x ULN)</p>
</td>
<td class="Botrule Lrule" align="center"><p class="First">68%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">60%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">78%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">71%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">HBeAg seroconversion</p></td>
<td class="Botrule Lrule" align="center"><p class="First">21%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">18%</p></td>
<td class="Botrule Lrule" align="center"><p class="First">NA</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">NA</p></td>
</tr>
</tbody>
</table>
<p>Histologic Improvement was independent of baseline levels of HBV DNA or ALT.</p>
<p><span class="Bold">Lamivudine-refractory Subjects with Compensated Liver Disease </span></p>
<p>Study AI463026 was a multinational, randomized, double-blind study of entecavir in 286 (of 293 randomized) subjects with lamivudine-refractory <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and compensated liver disease. Subjects receiving lamivudine at study entry either switched to entecavir 1 mg once daily (with neither a washout nor an overlap period) or continued on lamivudine 100 mg for a minimum of 52 weeks. The mean age of subjects was 39 years, 76% were male, 37% were Asian, 62% were Caucasian, and 52% had previously received interferon-Î±. The mean duration of prior lamivudine therapy was 2.7 years, and 85% had lamivudine resistance substitutions at baseline by an investigational line probe assay. At baseline, subjects had a mean Knodell Necroinflammatory Score of 6.5, mean serum HBV DNA as measured by Roche COBAS Amplicor PCR assay was 9.36 log<span class="Sub">10</span> copies/mL, and mean serum ALT level was 128 U/L. Paired, adequate liver biopsy samples were available for 87% of subjects.</p>
<p>Entecavir was superior to lamivudine on a primary endpoint of Histologic Improvement (using the Knodell Score at Week 48). These results and change in Ishak <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">Fibrosis</span> Score are shown in <span class="Bold">Table 10</span>. <span class="Bold">Table 11</span> shows selected virologic, biochemical, and serologic endpoints.</p>
<a name="_RefID273732B20C954116A6BD2C31F3129CCF"></a><table width="100%">
<caption><span>Table 10: Histologic Improvement and Change in Ishak <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">Fibrosis</span> Score at Week 48, Lamivudine-Refractory Subjects in Study AI463026 </span></caption>
<col width="25%">
<col width="12%">
<col width="14%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-17" href="#footnote-reference-17">*</a></dt>
<dd>Subjects with evaluable baseline histology (baseline Knodell Necroinflammatory Score â‰¥ 2).</dd>
<dt><a name="footnote-18" href="#footnote-reference-18">â€ </a></dt>
<dd>â‰¥ 2 point decrease in Knodell Necroinflammatory Score from baseline with no worsening of the Knodell <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">Fibrosis</span> Score.</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">â€¡</a></dt>
<dd>For Ishak <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">Fibrosis</span> Score, improvement = â‰¥ 1 point decrease from baseline and worsening = â‰¥ 1 point increase from baseline.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First"><span class="Bold">Entecavir</span><br><span class="Bold">1 mg</span><br><span class="Bold">n = 124</span><a name="footnote-reference-17" href="#footnote-17" class="Sup">*</a></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Lamivudine</span></p>
<p><span class="Bold">100 mg</span></p>
<p><span class="Bold">n = 116</span><a href="#footnote-17" class="Sup">*</a></p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold">Histologic Improvement (Knodell Scores)</span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First">Improvement<a name="footnote-reference-18" href="#footnote-18" class="Sup">â€ </a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">55%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">28%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">No improvement</p></td>
<td class="Botrule Lrule" align="center"><p class="First">34%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">57%</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First"><span class="Bold">Ishak <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">Fibrosis</span> Score</span></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First">Improvement<a name="footnote-reference-19" href="#footnote-19" class="Sup">â€¡</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">34%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">No change</p></td>
<td class="Botrule Lrule" align="center"><p class="First">44%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">42%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">Worsening<a href="#footnote-19" class="Sup">â€¡</a></p></td>
<td class="Botrule Lrule" align="center"><p class="First">11%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">26%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">Missing Week 48 biopsy</p></td>
<td class="Botrule Lrule" align="center"><p class="First">11%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16%</p></td>
</tr>
</tbody>
</table>
<a name="_RefIDCD4752B3E99C4B8AA3E37DB85B6DF16B"></a><table width="100%">
<caption><span>Table 11: Selected Virologic, Biochemical, and Serologic Endpoints at Week 48, Lamivudine-Refractory Subjects in Study AI463026 </span></caption>
<col width="45%">
<col width="12%">
<col width="14%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-20" href="#footnote-reference-20">*</a></dt>
<dd>Roche COBAS Amplicor PCR assay (LLOQ = 300 copies/mL).</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First"><span class="Bold">Entecavir</span><br><span class="Bold">1 mg</span></p>
<p><span class="Bold">n = 141</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First"><span class="Bold">Lamivudine</span></p>
<p><span class="Bold">100 mg</span></p>
<p><span class="Bold">n = 145</span></p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"><p class="First">HBV DNA<a name="footnote-reference-20" href="#footnote-20" class="Sup">*</a></p></td></tr>
<tr>
<td class="Botrule Lrule"><p class="First"> Proportion undetectable (&lt; 300 <br> copies/mL)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">19%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First"> Mean change from baseline (log<span class="Sub">10 </span>copies/mL)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-5.11</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-0.48</p></td>
</tr>
<tr>
<td class="Botrule Lrule"><p class="First">ALT normalization (â‰¤ 1 x ULN)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">61%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15%</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule"><p class="First">HBeAg seroconversion</p></td>
<td class="Botrule Lrule" align="center"><p class="First">8%</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3%</p></td>
</tr>
</tbody>
</table>
<p>Histologic Improvement was independent of baseline levels of HBV DNA or ALT.</p>
<p><span class="Bold"><span class="Italics">Subjects with Decompensated Liver Disease</span></span></p>
<p>Study AI463048 was a randomized, open-label study of entecavir 1 mg once daily versus adefovir dipivoxil 10 mg once daily in 191 (of 195 randomized) adult subjects with HBeAg-positive or -negative chronic HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and evidence of hepatic decompensation, defined as a Child-Turcotte-Pugh (CTP) score of 7 or higher. Subjects were either HBV-treatment-naÃ¯ve or previously treated, predominantly with lamivudine or interferon-Î±. </p>
<p>In Study AI463048, 100 subjects were randomized to treatment with entecavir and 91 subjects to treatment with adefovir dipivoxil. Two subjects randomized to treatment with adefovir dipivoxil actually received treatment with entecavir for the duration of the study. The mean age of subjects was 52 years, 74% were male, 54% were Asian, 33% were Caucasian, and 5% were Black/African American. At baseline, subjects had a mean serum HBV DNA by PCR of 7.83 log<span class="Sub">10</span> copies/mL and mean ALT level of 100 U/L; 54% of subjects were HBeAg-positive; 35% had genotypic evidence of lamivudine resistance. The baseline mean CTP score was 8.6. Results for selected study endpoints at Week 48 are shown in <span class="Bold">Table 12</span>. </p>
<a name="_RefID19778FE530BF4E6780A622EB44F05130"></a><table width="100%">
<caption><span>Table 12: Selected Endpoints at Week 48, Subjects With Decompensated Liver Disease, Study AI463048 </span></caption>
<col width="37%">
<col width="14%">
<col width="21%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-21" href="#footnote-reference-21">*</a></dt>
<dd>Endpoints were analyzed using intention-to-treat (ITT) method, treated subjects as randomized.</dd>
<dt><a name="footnote-22" href="#footnote-reference-22">â€ </a></dt>
<dd>Roche COBAS Amplicor PCR assay (LLOQ = 300 copies/mL).</dd>
<dt><a name="footnote-23" href="#footnote-reference-23">â€¡</a></dt>
<dd>Defined as decrease or no change from baseline in CTP score.</dd>
<dt><a name="footnote-24" href="#footnote-reference-24">Â§</a></dt>
<dd>Denominator is subjects with abnormal values at baseline.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule"></td>
<td class="Botrule Toprule" align="center">
<p class="First"><span class="Bold">Entecavir </span></p>
<p><span class="Bold">1 mg</span><br><span class="Bold">n = 100</span><a name="footnote-reference-21" href="#footnote-21" class="Sup">*</a></p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First"><span class="Bold">Adefovir Dipivoxil</span></p>
<p><span class="Bold">10 mg</span><br><span class="Bold">n = 91</span><a href="#footnote-21" class="Sup">*</a><span class="Bold">Â  </span></p>
</td>
</tr>
<tr><td colspan="3"><p class="First">HBV DNA<a name="footnote-reference-22" href="#footnote-22" class="Sup">â€ </a>Â </p></td></tr>
<tr>
<td><p class="First"> Proportion undetectable <br> (&lt; 300 copies/mL)</p></td>
<td align="center"><p class="First">57%</p></td>
<td align="center"><p class="First">20%</p></td>
</tr>
<tr>
<td><p class="First"> Stable or improved CTP score<a name="footnote-reference-23" href="#footnote-23" class="Sup">â€¡</a></p></td>
<td align="center"><p class="First">61%</p></td>
<td align="center"><p class="First">67%</p></td>
</tr>
<tr>
<td><p class="First"> HBsAg loss</p></td>
<td align="center"><p class="First">5%</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"> Normalization of ALT (â‰¤ 1 x ULN)<a name="footnote-reference-24" href="#footnote-24" class="Sup">Â§</a></p></td>
<td class="Botrule" align="center"><p class="First">49/78 (63%)</p></td>
<td class="Botrule" align="center"><p class="First">33/71 (46%)</p></td>
</tr>
</tbody>
</table>
<p>ULN = upper limit of normal.</p>
<p><span class="Bold"><span class="Italics">Subjects Co-infected with HIV and HBV</span></span></p>
<p>Study AI463038 was a randomized, double-blind, placebo-controlled study of entecavir versus placebo in 68 subjects co-infected with HIV and HBV who experienced recurrence of HBV <span class="product-label-link" type="condition" conceptid="133327" conceptname="Viremia">viremia</span> while receiving a lamivudine-containing highly active antiretroviral (HAART) regimen. Subjects continued their lamivudine-containing HAART regimen (lamivudine dose 300 mg/day) and were assigned to add either entecavir 1 mg once daily (51 subjects) or placebo (17 subjects) for 24 weeks followed by an open-label phase for an additional 24 weeks where all subjects received entecavir. At baseline, subjects had a mean serum HBV DNA level by PCR of 9.13 log<span class="Sub">10</span> copies/mL. Ninety-nine percent of subjects were HBeAg-positive at baseline, with a mean baseline ALT level of 71.5 U/L. Median HIV RNA level remained stable at approximately 2 log<span class="Sub">10</span> copies/mL through 24 weeks of blinded therapy. Virologic and biochemical endpoints at Week 24 are shown in <span class="Bold">Table 13</span>. There are no data in patients with HIV/HBV co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> who have not received prior lamivudine therapy. Entecavir has not been evaluated in HIV/HBV co-infected patients who were not simultaneously receiving effective HIV treatment [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_id_4c0e552a-fb83-400d-a62f-52d7ed779778">5.2</a>)</span>]. </p>
<a name="_RefIDB80F46ED0EC44ED1808F857F943DA22F"></a><table width="100%">
<caption><span>Table 13: Virologic and Biochemical Endpoints at Week 24, Study AI463038 </span></caption>
<col width="32%">
<col width="18%">
<col width="11%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-25" href="#footnote-reference-25">*</a></dt>
<dd>All subjects also received a lamivudine-containing HAART regimen.</dd>
<dt><a name="footnote-26" href="#footnote-reference-26">â€ </a></dt>
<dd>Roche COBAS Amplicor PCR assay (LLOQ = 300 copies/mL).</dd>
<dt><a name="footnote-27" href="#footnote-reference-27">â€¡</a></dt>
<dd>Percentage of subjects with abnormal ALT (&gt; 1 x ULN) at baseline who achieved ALT normalization (n = 35 for entecavir and n = 12 for placebo).</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule"></td>
<td class="Botrule Toprule" align="center">
<p class="First"><span class="Bold">Entecavir 1 mg</span><a name="footnote-reference-25" href="#footnote-25" class="Sup">*</a></p>
<p><span class="Bold">n = 51</span></p>
</td>
<td class="Botrule Toprule" align="center">
<p class="First"><span class="Bold">Placebo</span><a href="#footnote-25" class="Sup">*</a></p>
<p><span class="Bold">n = 17</span></p>
</td>
</tr>
<tr><td colspan="3"><p class="First">HBV DNA<a name="footnote-reference-26" href="#footnote-26" class="Sup">â€ </a>Â </p></td></tr>
<tr>
<td><p class="First"> Proportion undetectable <br> (&lt; 300 copies/mL)</p></td>
<td align="center"><p class="First">6%</p></td>
<td align="center"><p class="First">0</p></td>
</tr>
<tr>
<td><p class="First"> Mean change from baseline <br> (log<span class="Sub">10</span> copies/mL)</p></td>
<td align="center"><p class="First">-3.65</p></td>
<td align="center"><p class="First">+0.11</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">ALT normalization (â‰¤ 1 x ULN)</p></td>
<td class="Botrule" align="center"><p class="First">34%<a name="footnote-reference-27" href="#footnote-27" class="Sup">â€¡</a></p></td>
<td class="Botrule" align="center"><p class="First">8%<a href="#footnote-27" class="Sup">â€¡</a></p></td>
</tr>
</tbody>
</table>
<p>For subjects originally assigned to entecavir, at the end of the open-label phase (Week 48), 8% of subjects had HBV DNA &lt; 300 copies/mL by PCR, the mean change from baseline HBV DNA by PCR was -4.20 log<span class="Sub">10</span> copies/mL, and 37% of subjects with abnormal ALT at baseline had ALT normalization (â‰¤ 1 x ULN).</p>
<p><span class="Bold">Beyond 48 Weeks</span></p>
<p>The optimal duration of therapy with entecavir is unknown. According to protocol-mandated criteria in the Phase 3 clinical trials, subjects discontinued entecavir or lamivudine treatment after 52 weeks according to a definition of response based on HBV virologic suppression (&lt; 0.7 MEq/mL by bDNA assay) and loss of HBeAg (in HBeAg-positive subjects) or ALT &lt; 1.25 x ULN (in HBeAg-negative subjects) at Week 48. Subjects who achieved virologic suppression but did not have serologic response (HBeAg-positive) or did not achieve ALT &lt; 1.25 x ULN (HBeAg-negative) continued blinded dosing through 96 weeks or until the response criteria were met. These protocol-specified subject management guidelines are not intended as guidance for clinical practice.</p>
<p><span class="Bold"><span class="Italics">Nucleoside-inhibitor-naÃ¯ve Subjects</span></span></p>
<p>Among nucleoside-inhibitor-naÃ¯ve, HBeAg-positive subjects (Study AI463022), 243 (69%) entecavir-treated subjects and 164 (46%) lamivudine-treated subjects continued blinded treatment for up to 96 weeks. Of those continuing blinded treatment in Year 2, 180 (74%) entecavir subjects and 60 (37%) lamivudine subjects achieved HBV DNA &lt; 300 copies/mL by PCR at the end of dosing (up to 96 weeks). 193 (79%) entecavir subjects achieved ALT â‰¤ 1 x ULN compared to 112 (68%) lamivudine subjects, and HBeAg seroconversion occurred in 26 (11%) entecavir subjects and 20 (12%) lamivudine subjects.</p>
<p>Among nucleoside-inhibitor-naÃ¯ve, HBeAg-positive subjects, 74 (21%) entecavir subjects and 67 (19%) lamivudine subjects met the definition of response at Week 48, discontinued study drugs, and were followed off treatment for 24 weeks. Among entecavir responders, 26 (35%) subjects had HBV DNA &lt; 300 copies/mL, 55 (74%) subjects had ALT â‰¤ 1 x ULN, and 56 (76%) subjects sustained HBeAg seroconversion at the end of follow-up. Among lamivudine responders, 20 (30%) subjects had HBV DNA &lt; 300 copies/mL, 41 (61%) subjects had ALT â‰¤ 1 x ULN, and 47 (70%) subjects sustained HBeAg seroconversion at the end of follow-up.</p>
<p>Among nucleoside-inhibitor-naÃ¯ve, HBeAg-negative subjects (Study AI463027), 26 (8%) entecavir-treated subjects and 28 (9%) lamivudine-treated subjects continued blinded treatment for up to 96 weeks. In this small cohort continuing treatment in Year 2, 22 entecavir and 16 lamivudine subjects had HBV DNA &lt; 300 copies/mL by PCR, and 7 and 6 subjects, respectively, had ALT â‰¤ 1 x ULN at the end of dosing (up to 96 weeks).</p>
<p>Among nucleoside-inhibitor-naÃ¯ve, HBeAg-negative subjects, 275 (85%) entecavir subjects and 245 (78%) lamivudine subjects met the definition of response at Week 48, discontinued study drugs, and were followed off treatment for 24 weeks. In this cohort, very few subjects in each treatment arm had HBV DNA &lt; 300 copies/mL by PCR at the end of follow-up. At the end of follow-up, 126 (46%) entecavir subjects and 84 (34%) lamivudine subjects had ALT â‰¤ 1 x ULN.</p>
<p><span class="Bold"><span class="Italics">Lamivudine-refractory Subjects</span></span></p>
<p>Among lamivudine-refractory subjects (Study AI463026), 77 (55%) entecavir-treated subjects and 3 (2%) lamivudine subjects continued blinded treatment for up to 96 weeks. In this cohort of entecavir subjects, 31 (40%) subjects achieved HBV DNA &lt; 300 copies/mL, 62 (81%) subjects had ALT â‰¤ 1 x ULN, and 8 (10%) subjects demonstrated HBeAg seroconversion at the end of dosing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_16720c95-09ee-4b0d-a99c-1b7d67faed92"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Outcomes in Pediatric Subjects</h2>
<p class="First">Pediatric use information is approved for Bristol-Myers Squibb Companyâ€™s Baraclude<span class="Sup">Â®</span> (entecavir) tablets. However, due to Bristol-Myers Squibb Companyâ€™s marketing exclusivity rights, this drug product is not labeled with that information.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_76860f33-dbdc-45c4-89e0-a54e69ba6da5"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Entecavir Tablets, 0.5 mg are available as white to off-white, round, unscored, film-coated tablets, debossed with â€œTEVAâ€? on one side and â€œ5786â€? on the other side packaged in bottles of 30 and 90 tablets.</p>
<p>Entecavir Tablets, 1 mg are available as light-pink to pink, round, unscored, film-coated tablets, debossed with â€œTEVAâ€? on one side and â€œ5787â€? on the other side packaged in bottles of 30 tablets.</p>
<p><span class="Bold">Storage </span></p>
<p>Entecavir Tablets should be stored in a tightly closed container at 20Â° to 25Â° C (68Â° to 77Â° F) [See USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_66739a54-e0a0-4bf7-a67b-35003928441c"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-approved patient labeling (Patient Information). </p>
<p><span class="Bold">Information about Treatment</span></p>
<p>Physicians should inform their patients of the following important points when initiating entecavir treatment:</p>
<dl>
<dt>â€¢</dt>
<dd>Patients should remain under the care of a physician while taking entecavir. They should discuss any new symptoms or concurrent medications with their physician. </dd>
<dt>â€¢</dt>
<dd>Patients should be advised that treatment with entecavir has not been shown to reduce the risk of transmission of HBV to others through sexual contact or blood contamination. </dd>
<dt>â€¢</dt>
<dd>Patients should be advised to take entecavir on an empty stomach (at least 2 hours after a meal and 2 hours before the next meal).</dd>
<dt>â€¢</dt>
<dd>Patients should be advised to take a missed dose as soon as remembered unless it is almost time for the next dose. Patients should not take two doses at the same time. </dd>
<dt>â€¢</dt>
<dd>Patients should be advised that treatment with entecavir will not cure HBV. </dd>
<dt>â€¢</dt>
<dd>Patients should be informed that entecavir may lower the amount of HBV in the body, may lower the ability of HBV to multiply and infect new liver cells, and may improve the condition of the liver. </dd>
<dt>â€¢</dt>
<dd>Patients should be informed that it is not known whether entecavir will reduce their chances of getting liver cancer or cirrhosis. </dd>
</dl>
<p><span class="Bold">Post-treatment Exacerbation of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span></span></p>
<p>Patients should be informed that deterioration of liver disease may occur in some cases if treatment is discontinued, and that they should discuss any change in regimen with their physician.</p>
<p><span class="Bold">HIV/HBV Co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></span></p>
<p>Patients should be offered HIV antibody testing before starting entecavir therapy. They should be informed that if they have <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> and are not receiving effective HIV treatment, entecavir may increase the chance of HIV resistance to HIV medication.</p>
<p>All brand names listed are the registered trademarks of their respective owners and are not trademarks of TEVA Pharmaceuticals USA.</p>
<p>Manufactured In Israel By:</p>
<p><span class="Bold">TEVA PHARMACEUTICAL IND. LTD.</span></p>
<p>Jerusalem, 91010, Israel</p>
<p>Manufactured For:</p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA</span></p>
<p>Sellersville, PA 18960</p>
<p>Rev. B 7/2014</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_duplicate_id_5c4976a6-3177-44e9-84d4-5ed2beff4aad"></a><a name="section-16"></a><p></p>
<h1>Patient Information</h1>
<p class="First"><span class="Bold">Entecavir (en-TEK-a-vir) Tablets</span></p>
<p>Read this Patient Information before you start taking entecavir tablets and each time you get a refill. There may be new information. This information does not take the place of talking with your healthcare provider about your medical condition or treatment.</p>
<p><span class="Bold">What is the most important information I should know about entecavir tablets?</span></p>
<p><span class="Bold">1. Your <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> may get worse if you stop taking entecavir tablets.</span> This usually happens within 6 months after stopping entecavir tablets.</p>
<dl>
<dt>â€¢</dt>
<dd>Take entecavir tablets exactly as prescribed. </dd>
<dt>â€¢</dt>
<dd>Do not run out of entecavir tablets. </dd>
<dt>â€¢</dt>
<dd>Do not stop entecavir tablets without talking to your healthcare provider.</dd>
<dt>â€¢</dt>
<dd>Your healthcare provider should monitor your health and do regular blood tests to check your liver if you stop taking entecavir tablets.</dd>
</dl>
<p><span class="Bold">2. If you have or get HIV that is not being treated with medicines while taking entecavir tablets, the HIV virus may develop resistance to certain HIV medicines and become harder to treat.</span> You should get an HIV test before you start taking entecavir tablets and anytime after that when there is a chance you were exposed to HIV. </p>
<p><span class="Bold">Entecavir tablets can cause serious side effects including:</span></p>
<p><span class="Bold">3. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> (buildup of acid in the blood). Some people who have taken entecavir tablets or medicines like entecavir tablets (a nucleoside analogue) have developed a serious condition called <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>.</span> <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> is a serious medical emergency that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">Lactic acidosis</span> must be treated in the hospital. Reports of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> with entecavir tablets generally involved patients who were seriously ill due to their liver disease or other medical condition.</p>
<p><span class="Bold">Call your healthcare provider right away if you get any of the following signs or symptoms of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span>:</span></p>
<dl>
<dt>â€¢</dt>
<dd>You feel very weak or tired. </dd>
<dt>â€¢</dt>
<dd>You have unusual (not normal) <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>. </dd>
<dt>â€¢</dt>
<dd>You have trouble breathing. </dd>
<dt>â€¢</dt>
<dd>You have <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> with <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. </dd>
<dt>â€¢</dt>
<dd>You feel <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, especially in your arms and legs. </dd>
<dt>â€¢</dt>
<dd>You feel dizzy or light-headed. </dd>
<dt>â€¢</dt>
<dd>You have a fast or irregular heartbeat.</dd>
</dl>
<p><span class="Bold">4. Serious liver problems. Some people who have taken medicines like entecavir tablets have developed serious liver problems called hepatotoxicity, with <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">liver enlargement</span> (<span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>) and fat in the liver (steatosis). <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">Hepatomegaly</span> with steatosis is a serious medical emergency that can cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</span></p>
<p><span class="Bold">Call your healthcare provider right away if you get any of the following signs or symptoms of liver problems:</span></p>
<dl>
<dt>â€¢</dt>
<dd>Your skin or the white part of your eyes turns yellow (<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>). </dd>
<dt>â€¢</dt>
<dd>Your urine turns dark. </dd>
<dt>â€¢</dt>
<dd>Your bowel movements (stools) turn light in color. </dd>
<dt>â€¢</dt>
<dd>You donâ€™t feel like eating food for several days or longer. </dd>
<dt>â€¢</dt>
<dd>You feel sick to your stomach (<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>). </dd>
<dt>â€¢</dt>
<dd>You have lower <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>.</dd>
</dl>
<p>You may be more likely to get <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> or serious liver problems if you are female, very overweight, or have been taking nucleoside analogue medicines, like entecavir tablets, for a long time.</p>
<p><span class="Bold">What are entecavir tablets? </span></p>
<p>Entecavir tablets are a prescription medicine used to treat <span class="product-label-link" type="condition" conceptid="200763" conceptname="Chronic hepatitis">chronic hepatitis</span> B virus (HBV) in adults who have active liver disease.</p>
<dl>
<dt>â€¢</dt>
<dd>Entecavir tablets will not cure HBV. </dd>
<dt>â€¢</dt>
<dd>Entecavir tablets may lower the amount of HBV in the body. </dd>
<dt>â€¢</dt>
<dd>Entecavir tablets may lower the ability of HBV to multiply and infect new liver cells. </dd>
<dt>â€¢</dt>
<dd>Entecavir tablets may improve the condition of your liver. </dd>
<dt>â€¢</dt>
<dd>It is not known whether entecavir tablets will reduce your chances of getting liver cancer or <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver damage</span> (cirrhosis), which may be caused by chronic HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</dd>
<dt>â€¢</dt>
<dd>It is not known if entecavir tablets are safe and effective for use in children less than 2 years of age.</dd>
</dl>
<p><span class="Bold">What should I tell my healthcare provider before taking entecavir tablets?</span></p>
<p>Before you take entecavir tablets, tell your healthcare provider if you:</p>
<dl>
<dt>â€¢</dt>
<dd>have kidney problems. Your entecavir tablets dose or schedule may need to be changed.</dd>
<dt>â€¢</dt>
<dd>have received medicine for HBV before. Some people, especially those who have already been treated with certain other medicines for HBV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, may develop resistance to entecavir tablets. These people may have less benefit from treatment with entecavir tablets and may have worsening of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> after resistant virus appears. Your healthcare provider will test the level of the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus in your blood regularly. </dd>
<dt>â€¢</dt>
<dd>have any other medical conditions. </dd>
<dt>â€¢</dt>
<dd>are pregnant or plan to become pregnant.Â  It is not known if entecavir will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant. </dd>
</dl>
<p><span class="Bold">Antiretroviral Pregnancy Registry. </span>If you take entecavir tablets while you are pregnant, talk to your healthcare provider about how you can take part in the Entecavir Antiretroviral Pregnancy Registry. The purpose of the pregnancy registry is to collect information about the health of you and your baby.</p>
<dl>
<dt>â€¢</dt>
<dd>are breastfeeding or plan to breastfeed. It is not known if entecavir can pass into your breast milk. You and your healthcare provider should decide if you will take entecavir tablets or breastfeed. </dd>
</dl>
<p><span class="Bold">Tell your healthcare provider about all the medicines you take, </span>including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you have taken a medicine to treat HBV in the past.</p>
<p>Know the medicines you take. Keep a list of your medicines with you to show your healthcare provider and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take entecavir tablets?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Take entecavir tablets exactly as your healthcare provider tells you to.</dd>
<dt>â€¢</dt>
<dd>Your healthcare provider will tell you how many entecavir tablets to take. </dd>
<dt>â€¢</dt>
<dd>Your healthcare provider will tell you when and how often to take entecavir tablets.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Take entecavir tablets on an empty stomach</span>, at least 2 hours after a meal and at least 2 hours before the next meal. </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Do not change your dose or stop taking entecavir tablets without talking to your healthcare provider</span>.Â  </dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">If you miss a dose of entecavir tablets, </span>take them as soon as you remember and then take your next dose at its regular time. If it is almost time for your next dose, skip the missed dose. Do not take two doses at the same time. Call your healthcare provider or pharmacist if you are not sure what to do.</dd>
<dt>â€¢</dt>
<dd>When your supply of entecavir tablets starts to run low, call your healthcare provider or pharmacy for a refill. <span class="Bold">Do not run out of entecavir tablets</span>.</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">If you take too many entecavir tablets, </span>call your healthcare provider or go to the nearest emergency room right away.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of entecavir tablets?</span></p>
<p><span class="Bold">Entecavir tablets may cause serious side effects. </span>See <span class="Bold">â€œWhat is the most important information I should know about entecavir tablets?â€?</span></p>
<p><span class="Bold">The most common side effects of entecavir tablets include:</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></dd>
</dl>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away. </p>
<p>These are not all the possible side effects of entecavir tablets. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store entecavir tablets?</span></p>
<dl>
<dt>â€¢</dt>
<dd>Store entecavir tablets at room temperature, 20Â° to 25Â° C (68Â° to 77Â° F).</dd>
<dt>â€¢</dt>
<dd>Keep entecavir tablets in a tightly closed container.</dd>
<dt>â€¢</dt>
<dd>Safely throw away entecavir tablets that are out of date or no longer needed. Dispose of unused medicines through community take-back disposal programs when available or place entecavir tablets in an unrecognizable closed container in the household trash.</dd>
</dl>
<p><span class="Bold">Keep entecavir tablets and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General information about the safe and effective use of entecavir tablets </span></p>
<p>Entecavir tablets do not stop you from spreading the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B virus (HBV) to others by sex, sharing needles, or being exposed to your blood. Talk with your healthcare provider about safe sexual practices that protect your partner. Never share needles. Do not share personal items that can have blood or body fluids on them, like toothbrushes or razor blades. A shot (vaccine) is available to protect people at risk from becoming infected with HBV. </p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use entecavir tablets for a condition for which they were not prescribed. Do not give entecavir tablets to other people, even if they have the same symptoms you have. They may harm them. </p>
<p>This Patient Information leaflet summarizes the most important information about entecavir tablets. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about entecavir tablets that is written for health professionals. </p>
<p>For more information, call 1-888-838-2872.</p>
<p><span class="Bold">What are the ingredients in entecavir tablets? </span></p>
<p>Active ingredient:Â entecavir monohydrate</p>
<p>Inactive ingredients:Â crospovidone, magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, pregelatinized starch, talc, and titanium dioxide. In addition, the 1 mg contains FD&amp;C blue #2 aluminum lake, FD&amp;C red #40 aluminum lake, and iron oxide yellow.</p>
<p>This Patient Information has been approved by the U.S. Food and Drug Administration.</p>
<p><span class="Bold">Pediatric use information is approved for Bristol-Myers Squibb Companyâ€™s Baraclude<span class="Sup">Â®</span>(entecavir) tablets. However, due to Bristol-Myers Squibb Companyâ€™s marketing exclusivity rights, this drug product is not labeled with that information.</span></p>
<p>Manufactured In Israel By:</p>
<p><span class="Bold">TEVA PHARMACEUTICAL IND. LTD.</span></p>
<p>Jerusalem, 91010, Israel</p>
<p>Manufactured For:</p>
<p><span class="Bold">TEVA PHARMACEUTICALS USA</span></p>
<p>Sellersville, PA 18960</p>
<p>Iss. 7/2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_edcd05a2-a187-4c2d-8cc4-4e10351d534c"></a><a name="section-17"></a><p></p>
<h1>Package/Label Display Panel</h1>
<div class="Figure">
<a name="id19826459"></a><img alt="Entecavir Tablets 0.5 mg, 30s Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e527b81a-5e15-4b58-91ed-3df45f3ac589&amp;name=image-02.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a3bc0263-c8ac-4535-b27c-dc8196ca0b8e"></a><a name="section-17.1"></a><p></p>
<h2>Entecavir Tablets 0.5 mg, 30s Label Text</h2>
<p class="First"><span class="Bold">NDC</span> 0093-<span class="Bold">5786</span>-56</p>
<p><span class="Bold">ENTECAVIR</span></p>
<p><span class="Bold">Tablets</span></p>
<p><span class="Bold">0.5 mg</span></p>
<p>PHARMACIST:  PLEASE DISPENSE WITH</p>
<p>ATTACHED PATIENT INFORMATION LEAFLET</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">30 TABLETS</span></p>
<p><span class="Bold">TEVA</span></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_d948181b-72cf-40a4-bc1d-e35e9d26b5fa"></a><a name="section-18"></a><p></p>
<h1>Package/Label Display Panel</h1>
<div class="Figure">
<a name="id19826486"></a><img alt="Entecavir Tablets 1 mg, 30s Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e527b81a-5e15-4b58-91ed-3df45f3ac589&amp;name=image-03.jpg">
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ad7a59d8-57a7-4b84-9956-6da2a1377ff5"></a><a name="section-18.1"></a><p></p>
<h2>Entecavir Tablets 1 mg, 30s Label Text</h2>
<p class="First"><span class="Bold">NDC</span> 0093-<span class="Bold">5787</span>-56</p>
<p><span class="Bold">ENTECAVIR</span></p>
<p><span class="Bold">Tablets</span></p>
<p><span class="Bold">1 mg</span></p>
<p>PHARMACIST:  PLEASE DISPENSE WITH</p>
<p>ATTACHED PATIENT INFORMATION LEAFLET</p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">30 TABLETS</span></p>
<p><span class="Bold">TEVA</span></p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ENTECAVIRÂ 		
					</strong><br><span class="contentTableReg">entecavir tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0093-5786</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ENTECAVIR</strong> (ENTECAVIR ANHYDROUS) </td>
<td class="formItem">ENTECAVIR</td>
<td class="formItem">0.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3350</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TEVA;5786</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0093-5786-56</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">09/04/2014</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0093-5786-98</td>
<td class="formItem">90  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">09/04/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202122</td>
<td class="formItem">09/04/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ENTECAVIRÂ 		
					</strong><br><span class="contentTableReg">entecavir tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0093-5787</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ENTECAVIR</strong> (ENTECAVIR ANHYDROUS) </td>
<td class="formItem">ENTECAVIR</td>
<td class="formItem">1Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 3350</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 4000</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYVINYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>INDIGOTINDISULFONATE SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK (light-pink to pink) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">TEVA;5787</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0093-5787-56</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem">09/04/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202122</td>
<td class="formItem">09/04/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Teva Pharmaceuticals USA Inc
							(118234421)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 9/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>64f5bae6-0d50-481e-9641-30160f94146d</div>
<div>Set id: e527b81a-5e15-4b58-91ed-3df45f3ac589</div>
<div>Version: 1</div>
<div>Effective Time: 20140904</div>
</div>
</div>Â <div class="DistributorName">Teva Pharmaceuticals USA Inc</div></p>
</body></html>
